Page last updated: 2024-10-30

losartan and Cirrhosis

losartan has been researched along with Cirrhosis in 183 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research Excerpts

ExcerptRelevanceReference
" We hypothesized that the angiotensin receptor blocker (ARB) losartan would reduce inflammation by mitigating nuclear factor (NF)κB responses and promote T-cell recovery via inhibition of transforming growth factor-beta (TGFβ)-mediated fibrosis."9.41Losartan to reduce inflammation and fibrosis endpoints in HIV disease. ( Baker, JV; Collins, G; Deeks, S; Liappis, AP; Morse, C; Mystakelis, H; Neaton, J; Rhame, F; Rizza, S; Schacker, T; Sereti, I; Temesgen, Z; Tracy, RP; Wolfson, J, 2021)
"Losartan had no effect on lymphoid fibrosis or immune activation/inflammation."9.41Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial. ( Caballero, M; Diaz, A; Fabra, A; Garcia, F; Gatell, JM; Guardo, AC; Leal, L; Plana, M; Squarcia, M; Torres, B; Ugarte, A, 2021)
"The aim of this study was to evaluate the effects of losartan on left ventricular (LV) hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy (HCM)."9.17Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. ( Abbara, S; Baggish, AL; Fifer, MA; Ghoshhajra, BB; Ho, CY; Januzzi, JL; Lowry, PA; O'Callaghan, C; Passeri, JJ; Rothman, RD; Seidman, CE; Shimada, YJ; Yannekis, G, 2013)
"A PubMed/MEDLINE search of English-language articles (1990 to February 2006) with the terms angiotensin II antagonists or AIIAs or angiotensin receptor blockers or losartan or atenolol or beta blocker and terms including, but not limited to, atherosclerosis, left ventricular hypertrophy, carotid artery hypertrophy, fatty streaks, atrial fibrillation, arrhythmias, endothelial function, myocyte hypertrophy, myocardial fibrosis, platelet aggregation, tissue factor, plasminogen activator inhibitor-1, PAI-1, anti-inflammatory, uric acid, or oxidative stress."8.83Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. ( Díez, J, 2006)
" Unilateral ureteral obstruction (UUO) renal fibrosis model was established in mice by ligating the left ureter, and then randomly received losartan at a low dose (1 mg/kg) or a regular dose (3 mg/kg) for 2 weeks."8.31Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells. ( Gu, W; Huang, Z; Li, P; Li, TS; Liu, G; Nie, H; Peng, YH; Xiao, J, 2023)
"The purpose of this study was to examine the effect of topical and/or oral angiotensin converting enzyme II inhibitor and TGF-beta signaling blocker losartan on corneal stromal fibrosis that developed in rabbit corneas after Descemetorhexis removal of central Descemet's membrane and corneal endothelium."8.12Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits. ( Hilgert, GSL; Murillo, SE; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
"Via interaction with AT1R and MasRs, daidzein improved glomerulosclerosis, oxidative stress, and inflammation in UUO-OVX rats."8.12Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions. ( Askaripour, M; Jafari, E; Najafipour, H; Rajabi, S; Saberi, S, 2022)
"To evaluate the efficacy of losartan and prednisolone acetate in inhibiting corneal scarring fibrosis after alkali burn injury in rabbits."8.12Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
"To study the effect of topical losartan compared to vehicle on the generation of myofibroblasts and development of late haze scarring fibrosis after photorefractive keratectomy (PRK) in rabbits."8.12Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
"To investigate the effect of losartan on preventing bladder fibrosis and protecting renal function in rats with neurogenic paralysis bladder (NPB)."8.02Losartan prevents bladder fibrosis and protects renal function in rat with neurogenic paralysis bladder. ( Bauer, SB; Chen, Y; He, YL; Ji, FP; Liu, EP; Ma, Y; Pu, QS; Wang, QW; Wang, Y; Wen, JG; Wen, YB; Xing, D; Yang, XH; Zhai, RQ, 2021)
"In the present study, we tested the hypothesis that there are significant sex differences in angiotensin II (Ang II)-induced hypertension and kidney injury using male and female wildtype (WT) and proximal tubule-specific AT1a receptor knockout mice (PT-Agtr1a-/-)."8.02Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. ( Alexander, B; Casarini, DE; Hassan, R; Leite, APO; Li, XC; Zheng, X; Zhuo, JL, 2021)
" We herein examined the effect of EHP-101 on cardiac and other organ fibrosis in a mouse model induced by Angiotensin II."8.02EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice. ( Appendino, G; Caprioglio, D; García-Martín, A; Garrido-Rodríguez, M; Muñoz, E; Navarrete, C; Prados, ME, 2021)
" The aim of this study is to explore the renal fibrosis and investigate the effect of losartan on renal fibrosis after the obstruction' relief using an improved mouse model of relief for unilateral ureteral obstruction (RUUO)."7.91Losartan accelerates the repair process of renal fibrosis in UUO mouse after the surgical recanalization by upregulating the expression of Tregs. ( Jiang, C; Luo, J; Shi, GP; Song, J; Xia, Y; Yan, X; Zhang, M; Zhu, W, 2019)
"Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)."7.91Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019)
"Prehypertensive losartan treatment may lead to long‑term inhibition of the development of left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs)."7.85Hypomethylation of Agtrap is associated with long-term inhibition of left ventricular hypertrophy in prehypertensive losartan-treated spontaneously hypertensive rats. ( Lian, GL; Lin, X; Wang, HJ; Wang, TJ; Xie, LD; Xu, CS; Zhong, HB, 2017)
" Losartan stabilized all of these parameters and hindered the progression of fibrosis, but it did not reverse the pre-existing fibrotic manifestations."7.81Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. ( Arnoni, CP; Boim, MA; Maquigussa, E; Passos, CS; Pereira, LG, 2015)
"Liver regeneration, expected to decrease on day 3, was prolonged and increased even on day 5 despite antiangiogenic effects of Losartan and Spironolactone, which in fact inhibit fibrosis through phospho-Smad2 and increase regeneration."7.79Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: a pharmacologic dilemma on hepatocyte proliferation. ( Calıskan, K; Colakoglu, S; Colakoglu, T; Ezer, A; Karakaya, J; Kayaselcuk, F; Parlakgumus, A; Yildirim, S, 2013)
"This study examined the antifibrotic effect of losartan, an angiotensin II type 1 receptor antagonist, in an animal model of heart fibrosis induced by long-term intense exercise."7.79Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model. ( Benito, B; Brugada, J; Gay-Jordi, G; Guash, E; Mont, L; Nattel, S; Serrano-Mollar, A, 2013)
"To evaluate the in vivo effect of losartan - an angiotensin II receptor antagonist - on the course of chronic colitis-associated fibrosis and on TGF-b1 expression."7.78Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. ( Goldin, E; Israeli, E; Latella, G; Lysy, J; Metanes, I; Necozione, S; Papo, O; Pines, M; Wengrower, D; Zanninelli, G, 2012)
"Treatment with the selective VDR activator paricalcitol reduces myocardial fibrosis and preserves diastolic LV function due to pressure overload in a mouse model."7.78The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. ( Cannon, MV; de Boer, RA; Mahmud, H; Meems, LM; Ruifrok, WP; Silljé, HH; van Gilst, WH; Voors, AA, 2012)
"This study investigated the effects of losartan intervention on the expressions of hypoxia-inducible factor-1α (HIF-1α), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in renal fibrosis in rats with 5/6 nephrectomy."7.78Losartan alleviates renal fibrosis by down-regulating HIF-1α and up-regulating MMP-9/TIMP-1 in rats with 5/6 nephrectomy. ( Cheng, W; Fu, W; Jin, Z; Peng, W; Wang, H; Wang, Y; Yin, P; Zhou, H, 2012)
"To determine the role of angiotensin II (Ang II)/Ang II type 1 (AT(1)) receptor-coupled transforming growth factor (TGF)-β(1)/Smad signaling pathway in the AF-induced atrial fibrosis."7.77Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. ( Duan, DD; Gao, X; He, X; Lin, J; Ma, H; Peng, L; Wang, S; Zhu, Y, 2011)
"To investigate the effect of losartan on the expression of monocyte chemoattractant protein-1 (MCP1) and transforming growth factor-β(1) (TGF-β(1)) in the kidney of rats with unilateral urethral obstruction (UUO) and evaluate protective effect of losartan against reanal interstitial fibrosis."7.77[Effect of losartan on renal expression of monocyte chemoattractant protein-1 and transforming growth factor-β(1) in rats after unilateral ureteral obstruction]. ( Du, H; Fu, JZ; Huang, YY; Xu, AP; Zhou, SS, 2011)
"Losartan may reduce reactive fibrosis not only by attenuating the Ald signaling pathway but also by decreasing the expression of MR."7.74[Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. ( Bai, SC; Deng, LH; Huang, P; Su, L; Wen, YW; Wu, ZL; Xu, DL, 2008)
" We have investigated the effects of a long-acting calcium antagonist, benidipine, and an angiotensin AT(1) receptor antagonist, losartan, on the vascular damage observed in OLETF rats, an animal model of metabolic syndrome."7.74Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome. ( Furuta, K; Hongo, M; Ishizaka, N; Koike, K; Matsuzaki, G; Nagai, R; Saito, K; Sakurai, R, 2008)
" The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)."7.73Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005)
"Angiotensin II (Ang II) participates in the development of fibrosis during vascular damage."7.72Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. ( Blanco-Colio, LM; Egido, J; Esteban, V; Lorenzo, O; Ruiz-Ortega, M; Rupérez, M, 2003)
"This study was carried out to investigate the effects of early administration of losartan on ventricular remodelling (VR) in rabbits with experimental myocardial infarction (MI)."7.72[Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction]. ( Depetris Chauvin, A; Gelpi, RJ; González, GE; Mangas, F; Morales, C; Palleiro, J; Rodríguez, M, 2004)
"Losartan prevents apoptosis of pancreatic acinar cell by blocking AT1R during the development of pancreatic fibrosis."7.72Angiotensin II mediates acinar cell apoptosis during the development of rat pancreatic fibrosis by AT1R. ( Dong, Y; Wang, XP; Wu, K; Wu, L; Zhang, R, 2004)
"We divided 2-month-old male Sprague-Dawley rats into 4 groups, namely group 1-control, group 2-hyperoxaluria, group 3-hyperoxaluria plus losartan and group 4-losartan."7.71Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. ( Angerosa, M; De Cavanaugh, EM; Ferder, L; Inserra, F; Stella, I; Toblli, JE, 2002)
"Cardiac iron deposition may be involved in the development of cardiac fibrosis induced by angiotensin II."7.71Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. ( Ishizaka, N; Mitani, H; Mori, I; Nagai, R; Ohno, M; Saito, K; Sata, M; Usui, S; Yamazaki, I, 2002)
"To investigate the different effects of an angiotensin II type 1 (AT(1)) receptor antagonist, losartan, and an angiotensin converting enzyme (ACE) inhibitor, fosinopril, on cardiomyocyte apoptosis, myocardial fibrosis, and angiotensin II (Ang II) in the left ventricle of spontaneously hypertensive rats (SHRs)."7.71Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. ( Liang, X; Sun, M; Xie, X; Yang, T; Yu, G; Zhao, S, 2002)
"To investigate effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in the spontaneously hypertensive rats (SHR)."7.71[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. ( He, BX; Liang, XQ; Yu, GL, 2001)
"In cirrhotic patients without ascites, creatinine clearance, 24-h urinary sodium excretion, and fractional excretion of sodium were significantly increased after losartan administration."7.71One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites. ( Chang, FY; Hou, MC; Lee, FY; Lee, SD; Lee, WC; Lin, HC; Yang, YY, 2002)
" To determine if the TI injury accompanying cyclosporine A (CsA) nephropathy was associated with accelerated apoptosis and ischemia, we treated rats for five weeks with CsA with or without losartan (to block angiotensin II type 1 receptor), or hydralazine/furosemide (H/F) (protocol #1)."7.70Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. ( Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE, 1998)
"There was (1) low angiotensin receptor binding in normal myocardium; (2) markedly increased angiotensin II receptor binding at the site of left ventricular myocardial infarction and endocardial fibrosis of the interventricular septum at day 3 and weeks 1, 2, 4, and 8; (3) high angiotensin II receptor binding in the pericardial fibrosis that followed pericardiotomy, and in the fibrosis that appeared in response to suture insertion around the left coronary artery, in both infarcted and sham operated rats; (4) total displacement of normal and connective tissue angiotensin II receptor binding by DuP753, but not by PD123177; (5) ACE inhibition by lisinopril, but no change in angiotensin II receptor binding, at all sites of fibrosis; and (6) significant attenuation by lisinopril of collagen formation in the visceral pericardium of sham operated controls."7.69Angiotensin II receptor binding following myocardial infarction in the rat. ( Sun, Y; Weber, KT, 1994)
"Losartan is an angiotensin II receptor blocker (ARB) that impedes transforming growth factor (TGF) beta signaling by inhibiting activation of signal transduction molecule extracellular signal-regulated kinase (ERK)."7.01Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders. ( Wilson, SE, 2023)
"In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis."6.71Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004)
"Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)."6.71Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005)
"Losartan is a typical Angiotensin II (ANG II) receptor antagonist and relaxes blood vessels."5.72Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. ( Ma, Y; Yu, R; Zhou, X; Zou, J, 2022)
"Cardiac fibrosis is a severe condition with limited therapeutic options and often occurs in chronic cardiovascular diseases such as hypertension and myocardial infarction."5.72Integrin subunit β-like 1 mediates angiotensin II-induced myocardial fibrosis by regulating the forkhead box Q1/Snail axis. ( Chen, W; Han, L; Ji, H; Yu, L; Zhu, H, 2022)
"Losartan is an inhibitor of transforming growth factor-β signaling."5.72Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. ( Ambrósio, R; Bandeira, F; Pereira-Souza, AL; Salomão, MQ; Souza Lima, A; Wilson, SE, 2022)
"Losartan shows minimal adverse effects and no influence on graft function and biomarkers of graft fibrosis."5.51Short-term Effects of Losartan on Cardiovascular Risk and Allograft Injury Biomarkers in Kidney Transplant Recipients. ( Biedunkiewicz, B; Chamienia, A; Dębska-Ślizień, A; Głyda, M; Heleniak, Z; Konopa, J; Kuźmiuk-Glembin, I; Lizakowski, S; Pięta, R; Renke, M; Rutkowski, B; Tylicki, L, 2022)
"Pleural fibrosis is associated with various inflammatory processes such as tuberculous pleurisy and bacterial empyema."5.48Inhibition of angiotensin II and calpain attenuates pleural fibrosis. ( Greer, PA; Huang, H; Ma, WL; Shi, HZ; Song, LJ; Su, Y; Xiang, F; Xin, JB; Xiong, L; Xu, JJ; Yang, J; Ye, H; Yu, F, 2018)
" We hypothesized that the angiotensin receptor blocker (ARB) losartan would reduce inflammation by mitigating nuclear factor (NF)κB responses and promote T-cell recovery via inhibition of transforming growth factor-beta (TGFβ)-mediated fibrosis."5.41Losartan to reduce inflammation and fibrosis endpoints in HIV disease. ( Baker, JV; Collins, G; Deeks, S; Liappis, AP; Morse, C; Mystakelis, H; Neaton, J; Rhame, F; Rizza, S; Schacker, T; Sereti, I; Temesgen, Z; Tracy, RP; Wolfson, J, 2021)
"Losartan had no effect on lymphoid fibrosis or immune activation/inflammation."5.41Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial. ( Caballero, M; Diaz, A; Fabra, A; Garcia, F; Gatell, JM; Guardo, AC; Leal, L; Plana, M; Squarcia, M; Torres, B; Ugarte, A, 2021)
"Losartan treatment partially attenuated these responses."5.40Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. ( He, P; Li, D; Zhang, B, 2014)
"Losartan is a Food and Drug Administration approved antihypertensive medication that is recently emerging as an antifibrotic therapy."5.40Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. ( Corona, BT; Garg, K; Walters, TJ, 2014)
"Recent studies showed that chronic administration of losartan, an angiotensin II type I receptor antagonist, improved skeletal muscle function in dystrophin-deficient mdx mice."5.37Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. ( Gordish-Dressman, H; Guerron, AD; Hoffman, EP; Iantorno, M; Nagaraju, K; Rayavarapu, S; Sali, A; Spurney, CF; van der Meulen, J; Yu, Q, 2011)
"Fibrosis was accompanied by activation of pancreatic stellate cells (PSC) evaluated by Western blot analysis for alpha-smooth muscle actin."5.36Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. ( Neuschwander-Tetri, BA; Oshima, K; Talkad, V; Ulmasov, B; Xu, Z, 2010)
"Losartan treatment reduced the mortality of TG: Mean life span was raised from 116 to 193 days (n = 18 end, p < 0."5.36Losartan reduces mortality in a genetic model of heart failure. ( Baba, HA; Gergs, U; Grossmann, C; Günther, S; Hauptmann, S; Holzhausen, HJ; Jones, LR; Kusche, T; Neumann, J; Punkt, K, 2010)
"Losartan pretreated-rats presented diminished FN abundance in homogenates of cortex tissue from ischemic rats with or without reperfusion."5.32Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function. ( Barrilli, A; Elías, MM; Menacho, M; Molinas, S; Petrini, G, 2004)
"Tubulointerstitial fibrosis is considered to be common endpoint result of many forms of chronic renal diseases."5.31Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. ( Dai, C; Liu, Y; Yang, J, 2002)
"Aldosterone levels were not significantly elevated, suggesting direct proliferative effects of Ang II."5.30Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. ( Gray, GA; Kenyon, CJ; McEwan, PE; Sherry, L; Webb, DJ, 1998)
"Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure."5.29Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995)
"Losartan treatment decreased the tissue expression of miR-21 and TGF-β and tissue fibrosis in kidney transplant patient, and it had a protective effect on allograft function and may delay chronic allograft dysfunction by reducing mediators of fibrosis."5.27Downregulation of Profibrotic Gene Expression by Angiotensin Receptor Blockers. ( Nafar, M; Samavat, S; Shahraki, E, 2018)
" The aim of this randomised controlled trial was to assess whether treatment with Losartan for 96 weeks slowed, halted or reversed the progression of fibrosis in patients with non-alcoholic steatohepatitis (NASH)."5.24A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. ( Anstee, QM; Barnes, J; Burt, AD; Bury, Y; Day, CP; Goudie, N; Mann, D; McColl, E; McPherson, S; Steen, N; Stewart, S; Stocken, DD; Tiniakos, D; Wilkinson, J; Wilkinson, N, 2017)
"The aim of this study was to evaluate the effects of losartan on left ventricular (LV) hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy (HCM)."5.17Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. ( Abbara, S; Baggish, AL; Fifer, MA; Ghoshhajra, BB; Ho, CY; Januzzi, JL; Lowry, PA; O'Callaghan, C; Passeri, JJ; Rothman, RD; Seidman, CE; Shimada, YJ; Yannekis, G, 2013)
"To compare the effects of losartan and amlodipine on myocardial structure and function in hypertensive patients with Type 2 diabetes and left ventricular hypertrophy."5.16Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. ( Corradi, L; Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2012)
"In 204 patients with hypertension and left ventricular (LV) hypertrophy we measured serum concentration of carboxy-terminal telopeptide of type I procollagen (ICTP), carboxy-terminal propeptide of type I procollagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP), amino-terminal propeptide of type I procollagen (PINP) and LV mass by echocardiography at baseline and annually during 4 years of losartan- or atenolol-based antihypertensive treatment; 185 patients completed the study."5.12Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. ( Bang, LE; Christensen, MK; Devereux, RB; Fossum, E; Hildebrandt, P; Ibsen, H; Kjeldsen, SE; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K; Wiinberg, N, 2006)
" Inhibition of TGFβ signaling by Losartan treatment greatly improved the phenotype of myopathies associated with laminin-α2-deficient congenital muscular dystrophy."4.88TGFβ signaling: its role in fibrosis formation and myopathies. ( Cohn, RD; MacDonald, EM, 2012)
"A PubMed/MEDLINE search of English-language articles (1990 to February 2006) with the terms angiotensin II antagonists or AIIAs or angiotensin receptor blockers or losartan or atenolol or beta blocker and terms including, but not limited to, atherosclerosis, left ventricular hypertrophy, carotid artery hypertrophy, fatty streaks, atrial fibrillation, arrhythmias, endothelial function, myocyte hypertrophy, myocardial fibrosis, platelet aggregation, tissue factor, plasminogen activator inhibitor-1, PAI-1, anti-inflammatory, uric acid, or oxidative stress."4.83Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. ( Díez, J, 2006)
" THC was administered via daily oral gavage with the lipid carrier polyenylphosphatidylcholine (PPC) as add-on therapy to losartan (angiotensin receptor blocker) to examine effects on kidney oxidative stress and fibrosis."4.31Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury. ( Khazaali, M; Khazaeli, M; Lau, WL; Nunes, ACF; Prudente, J; Singh, B; Vaziri, ND; Zhao, Y, 2023)
" We studied the effect of a hybrid compound, GGN1231 (derived from losartan in which a powerful antioxidant was attached), on the prevention of cardiovascular damage, cardiac hypertrophy, and fibrosis in a rat model of severe chronic renal failure (CRF)."4.31Effects of a Losartan-Antioxidant Hybrid (GGN1231) on Vascular and Cardiac Health in an Experimental Model of Chronic Renal Failure. ( Alajarín, R; Alonso-Montes, C; Alvarez-Builla, J; Cannata-Andía, JB; Carrillo-López, N; Fernández-Villabrille, S; García-Navazo, G; Gutiérrez-Calabres, E; Martínez-Arias, L; Naves-Díaz, M; Panizo, S; Rodríguez-Puyol, D; Ruíz-Torres, MP; Vaquero-López, JJ, 2023)
"Male cardiac-specific BACH1 knockout mice or cardiac-specific BACH1 transgenic (BACH1-Tg) mice and their respective wild-type littermates developed cardiac hypertrophy induced by angiotensin II (Ang II) or transverse aortic constriction (TAC)."4.31Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway. ( Chen, L; Ge, F; Guo, J; He, Y; Hu, K; Jia, M; Jiang, L; Jin, J; Li, L; Li, Q; Lv, X; Ma, S; Meng, D; Osto, E; Wang, X; Wei, X; Wu, H; Wu, J; Yang, Z; Zhang, J; Zhi, X, 2023)
" Unilateral ureteral obstruction (UUO) renal fibrosis model was established in mice by ligating the left ureter, and then randomly received losartan at a low dose (1 mg/kg) or a regular dose (3 mg/kg) for 2 weeks."4.31Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells. ( Gu, W; Huang, Z; Li, P; Li, TS; Liu, G; Nie, H; Peng, YH; Xiao, J, 2023)
"The purpose of this study was to examine the effect of topical and/or oral angiotensin converting enzyme II inhibitor and TGF-beta signaling blocker losartan on corneal stromal fibrosis that developed in rabbit corneas after Descemetorhexis removal of central Descemet's membrane and corneal endothelium."4.12Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits. ( Hilgert, GSL; Murillo, SE; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
"Via interaction with AT1R and MasRs, daidzein improved glomerulosclerosis, oxidative stress, and inflammation in UUO-OVX rats."4.12Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions. ( Askaripour, M; Jafari, E; Najafipour, H; Rajabi, S; Saberi, S, 2022)
"To evaluate the efficacy of losartan and prednisolone acetate in inhibiting corneal scarring fibrosis after alkali burn injury in rabbits."4.12Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
"To study the effect of topical losartan compared to vehicle on the generation of myofibroblasts and development of late haze scarring fibrosis after photorefractive keratectomy (PRK) in rabbits."4.12Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022)
" Similar to losartan, Dojuksan ameliorated kidney inflammation and fibrosis in UUO mice."4.02Dojuksan ameliorates tubulointerstitial fibrosis through irisin-mediated muscle-kidney crosstalk. ( Dorotea, D; Ha, H; Jiang, S; Kim, DS; Oh, DS; Son, E, 2021)
"To investigate the effect of losartan on preventing bladder fibrosis and protecting renal function in rats with neurogenic paralysis bladder (NPB)."4.02Losartan prevents bladder fibrosis and protects renal function in rat with neurogenic paralysis bladder. ( Bauer, SB; Chen, Y; He, YL; Ji, FP; Liu, EP; Ma, Y; Pu, QS; Wang, QW; Wang, Y; Wen, JG; Wen, YB; Xing, D; Yang, XH; Zhai, RQ, 2021)
"In the present study, we tested the hypothesis that there are significant sex differences in angiotensin II (Ang II)-induced hypertension and kidney injury using male and female wildtype (WT) and proximal tubule-specific AT1a receptor knockout mice (PT-Agtr1a-/-)."4.02Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. ( Alexander, B; Casarini, DE; Hassan, R; Leite, APO; Li, XC; Zheng, X; Zhuo, JL, 2021)
" We herein examined the effect of EHP-101 on cardiac and other organ fibrosis in a mouse model induced by Angiotensin II."4.02EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice. ( Appendino, G; Caprioglio, D; García-Martín, A; Garrido-Rodríguez, M; Muñoz, E; Navarrete, C; Prados, ME, 2021)
" Delayed exercise after complex orthopaedic trauma results in decreased muscle fibrosis and improved pain Losartan, an angiotensin-receptor blocker with anti-fibrotic abilities, recapitulates the effect of exercise on post-injury recovery and may provide an enhanced recovery option for those who are unable to exercise after injury ABSTRACT: Chronic pain and disability after limb injury are major public health problems."3.96Angiotensin receptor blockade mimics the effect of exercise on recovery after orthopaedic trauma by decreasing pain and improving muscle regeneration. ( Clark, JD; Forman, TE; Goodman, SB; Paine, P; Pajarinen, J; Quarta, M; Rando, TA; Takemura, Y; Tawfik, VL, 2020)
"It has been described that the cardiac dysfunction in the obesity model is because of collagen imbalance and that angiotensin II (Ang II) contributes to myocardial fibrosis."3.96Increased angiotensin II from adipose tissue modulates myocardial collagen I and III in obese rats. ( Cicogna, AC; Corrêa, CR; da Silva-Bertani, DCT; de Oliveira, EM; de Souza, SLB; de Tomasi, LC; Fernandes, T; Freire, PP; Mota, GAF; Padovani, CR; Sant'Ana, PG; Vileigas, DF, 2020)
" The aim of this study is to explore the renal fibrosis and investigate the effect of losartan on renal fibrosis after the obstruction' relief using an improved mouse model of relief for unilateral ureteral obstruction (RUUO)."3.91Losartan accelerates the repair process of renal fibrosis in UUO mouse after the surgical recanalization by upregulating the expression of Tregs. ( Jiang, C; Luo, J; Shi, GP; Song, J; Xia, Y; Yan, X; Zhang, M; Zhu, W, 2019)
"Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)."3.91Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019)
" We test such interactions in the brain and cerebral vessels of TGF mice by measuring cerebrovascular reactivity, levels of protein markers of vascular fibrosis, nitric oxide synthase activity, astrogliosis, and mnemonic performance in mice treated (6 months) with the AT1R blocker losartan (10 mg/kg per day) or the angiotensin converting enzyme inhibitor enalapril (3 mg/kg per day)."3.88Transforming growth factor-β1 induces cerebrovascular dysfunction and astrogliosis through angiotensin II type 1 receptor-mediated signaling pathways. ( Hamel, E; Imboden, H; Lecrux, C; Nicolakakis, N; Ongali, B; Tong, XK, 2018)
"Angiotensin II (Ang II) has been regarded as an important profibrogenic cytokine in renal fibrosis."3.85KLF 15 Works as an Early Anti-Fibrotic Transcriptional Regulator in Ang II-Induced Renal Fibrosis via Down-Regulation of CTGF Expression. ( Fu, L; Gao, X; Gu, X; Mei, C; Wang, Y; Xu, D, 2017)
"Prehypertensive losartan treatment may lead to long‑term inhibition of the development of left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs)."3.85Hypomethylation of Agtrap is associated with long-term inhibition of left ventricular hypertrophy in prehypertensive losartan-treated spontaneously hypertensive rats. ( Lian, GL; Lin, X; Wang, HJ; Wang, TJ; Xie, LD; Xu, CS; Zhong, HB, 2017)
" The angiotensin II antagonist losartan, metabolized to the EXP3179 and EXP3174 metabolites, reduces myocardial fibrosis and LV stiffness in hypertensive patients."3.85Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. ( Beaumont, J; Díez, J; Fortuño, A; González, A; López, B; Miguel-Carrasco, JL; Moreno, MU; Ravassa, S; San José, G; Zalba, G, 2017)
"Thus, in our model of chronic renocardiac syndrome, combined treatments similarly decreased cardiac fibrosis and stabilized systolic function as losartan alone, perhaps suggesting a dominant role for a single factor such as angiotensin II type 1 (AT1) receptor activation or inflammation in the network of aberrant systems in the heart."3.85Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation. ( Bongartz, LG; Braam, B; Cheng, C; Cramer, MJ; Doevendans, PA; Gaillard, CA; Goldschmeding, R; Joles, JA; Oosterhuis, NR; van Koppen, A; Verhaar, MC; Xu, YJ, 2017)
" Losartan stabilized all of these parameters and hindered the progression of fibrosis, but it did not reverse the pre-existing fibrotic manifestations."3.81Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. ( Arnoni, CP; Boim, MA; Maquigussa, E; Passos, CS; Pereira, LG, 2015)
"To elucidate the reliability of MRI as a non-invasive tool for assessing in vivo muscle health and pathological amelioration in response to Losartan (Angiotensin II Type 1 receptor blocker) in DyW mice (mouse model for Laminin-deficient Congenital Muscular Dystrophy Type 1A)."3.81Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A). ( Accorsi, A; Girgenrath, M; Kumar, A; Vohra, R; Walter, G, 2015)
"The aim of this study was to evaluate the effect of compound 21 (C21), a selective AT2 receptor agonist, on diabetic nephropathy and the potential additive effect of C21, when associated with losartan treatment, on the development of albuminuria and renal fibrosis in Zucker diabetic fatty (ZDF) rats."3.80Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. ( Bombardi, C; Carletti, R; Castoldi, G; Dahlöf, B; di Gioia, CR; Maestroni, S; Steckelings, UM; Stella, A; Unger, T; Zerbini, G, 2014)
"Liver regeneration, expected to decrease on day 3, was prolonged and increased even on day 5 despite antiangiogenic effects of Losartan and Spironolactone, which in fact inhibit fibrosis through phospho-Smad2 and increase regeneration."3.79Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: a pharmacologic dilemma on hepatocyte proliferation. ( Calıskan, K; Colakoglu, S; Colakoglu, T; Ezer, A; Karakaya, J; Kayaselcuk, F; Parlakgumus, A; Yildirim, S, 2013)
"This study examined the antifibrotic effect of losartan, an angiotensin II type 1 receptor antagonist, in an animal model of heart fibrosis induced by long-term intense exercise."3.79Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model. ( Benito, B; Brugada, J; Gay-Jordi, G; Guash, E; Mont, L; Nattel, S; Serrano-Mollar, A, 2013)
"To evaluate the in vivo effect of losartan - an angiotensin II receptor antagonist - on the course of chronic colitis-associated fibrosis and on TGF-b1 expression."3.78Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. ( Goldin, E; Israeli, E; Latella, G; Lysy, J; Metanes, I; Necozione, S; Papo, O; Pines, M; Wengrower, D; Zanninelli, G, 2012)
"100 healthy Sprague-Dawley rats were randomly divided into 5 groups: Unilateral ureteral obstruction (UUO) group, sham-operation (SOR) group, Radix Notoginseng (RN) group, compound Radix Notoginseng (CRN) group and Losartan (ARB) group."3.78[Investigate the effects of compound radix notoginseng on renal interstitial fibrosis and kidney-targeting treatment]. ( Fan, JM; Feng, SG; Liu, HC; Xie, XS; Yuan, W; Zhang, CL; Zhang, ZY; Zuo, C, 2012)
" Losartan significantly attenuated the expression of TGF-β1 and Snail, and decreased kidney fibrosis induced by IS and PCS in vivo."3.78Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. ( Chang, SC; Sun, CY; Wu, MS, 2012)
"The activation of transforming growth factor-β1(TGF-β1)/Smad signaling pathway and increased expression of connective tissue growth factor (CTGF) induced by angiotensin II (AngII) have been proposed as a mechanism for atrial fibrosis."3.78Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts. ( Gu, J; Guo, M; Jiang, WF; Liu, X; Tan, HW; Wang, QX; Zhou, L, 2012)
"Treatment with the selective VDR activator paricalcitol reduces myocardial fibrosis and preserves diastolic LV function due to pressure overload in a mouse model."3.78The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. ( Cannon, MV; de Boer, RA; Mahmud, H; Meems, LM; Ruifrok, WP; Silljé, HH; van Gilst, WH; Voors, AA, 2012)
"This study investigated the effects of losartan intervention on the expressions of hypoxia-inducible factor-1α (HIF-1α), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in renal fibrosis in rats with 5/6 nephrectomy."3.78Losartan alleviates renal fibrosis by down-regulating HIF-1α and up-regulating MMP-9/TIMP-1 in rats with 5/6 nephrectomy. ( Cheng, W; Fu, W; Jin, Z; Peng, W; Wang, H; Wang, Y; Yin, P; Zhou, H, 2012)
"To determine the role of angiotensin II (Ang II)/Ang II type 1 (AT(1)) receptor-coupled transforming growth factor (TGF)-β(1)/Smad signaling pathway in the AF-induced atrial fibrosis."3.77Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. ( Duan, DD; Gao, X; He, X; Lin, J; Ma, H; Peng, L; Wang, S; Zhu, Y, 2011)
" The aim of this work was to assess the impact of hemin (heme oxygenase-1 inducer) on NADPH oxidase activation, cardiac oxidative stress, and development of fibrosis in a rat model of renovascular hypertensive cardiomyopathy in comparison to an anti-hypertensive reference treatment with losartan."3.77Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signalling. ( Belmokhtar, K; Bonnet, P; Eder, V; Khamis, G; Machet, MC; Vourc'h, P; Worou, ME, 2011)
"To investigate the effect of losartan on the expression of monocyte chemoattractant protein-1 (MCP1) and transforming growth factor-β(1) (TGF-β(1)) in the kidney of rats with unilateral urethral obstruction (UUO) and evaluate protective effect of losartan against reanal interstitial fibrosis."3.77[Effect of losartan on renal expression of monocyte chemoattractant protein-1 and transforming growth factor-β(1) in rats after unilateral ureteral obstruction]. ( Du, H; Fu, JZ; Huang, YY; Xu, AP; Zhou, SS, 2011)
"Losartan may reduce reactive fibrosis not only by attenuating the Ald signaling pathway but also by decreasing the expression of MR."3.74[Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. ( Bai, SC; Deng, LH; Huang, P; Su, L; Wen, YW; Wu, ZL; Xu, DL, 2008)
"The angiotensin converting enzyme inhibitor captopril prevents myosin-induced experimental autoimmune myocarditis."3.74Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis. ( Bahk, TJ; Daniels, MD; Engman, DM; Leon, JS; Wang, K, 2008)
" We have investigated the effects of a long-acting calcium antagonist, benidipine, and an angiotensin AT(1) receptor antagonist, losartan, on the vascular damage observed in OLETF rats, an animal model of metabolic syndrome."3.74Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome. ( Furuta, K; Hongo, M; Ishizaka, N; Koike, K; Matsuzaki, G; Nagai, R; Saito, K; Sakurai, R, 2008)
" The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)."3.73Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005)
"We examined the effects of combined treatment with SMP-534 and losartan on urinary albumin and glomerular fibrosis in db/db mice."3.73Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy. ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2006)
"Rats underwent unilateral ureteral obstruction and were given either drinking water or losartan for 21 days."3.73Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction. ( Chen, J; El Chaar, M; Felsen, D; Kellner, D; Poppas, D; Richardson, I; Seshan, SV; Vaughan, ED, 2006)
"The influence of chronic administration of losartan on gap junction conductance (gj), conduction velocity and interstitial fibrosis was investigated in the failing heart of 4-month-old cardiomyopathic hamsters (TO-2)."3.73Chronic blockade of angiotensin II AT1-receptors increased cell-to-cell communication, reduced fibrosis and improved impulse propagation in the failing heart. ( De Mello, WC; Specht, P, 2006)
"Angiotensin II (Ang II) participates in the development of fibrosis during vascular damage."3.72Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. ( Blanco-Colio, LM; Egido, J; Esteban, V; Lorenzo, O; Ruiz-Ortega, M; Rupérez, M, 2003)
"This study was carried out to investigate the effects of early administration of losartan on ventricular remodelling (VR) in rabbits with experimental myocardial infarction (MI)."3.72[Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction]. ( Depetris Chauvin, A; Gelpi, RJ; González, GE; Mangas, F; Morales, C; Palleiro, J; Rodríguez, M, 2004)
" We examined the effect of an angiotensin II receptor inhibitor (AT(1)) losartan, independent from its effects on blood pressure, on nitric oxide synthase (NOS) isoforms and cyclooxygenase-2 (COX-2) expression and the significance of this interaction on interstitial fibrosis in UUO."3.72Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. ( Carrizo, L; Manucha, W; Oliveros, L; Seltzer, A; Vallés, P, 2004)
"Losartan prevents apoptosis of pancreatic acinar cell by blocking AT1R during the development of pancreatic fibrosis."3.72Angiotensin II mediates acinar cell apoptosis during the development of rat pancreatic fibrosis by AT1R. ( Dong, Y; Wang, XP; Wu, K; Wu, L; Zhang, R, 2004)
"We divided 2-month-old male Sprague-Dawley rats into 4 groups, namely group 1-control, group 2-hyperoxaluria, group 3-hyperoxaluria plus losartan and group 4-losartan."3.71Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. ( Angerosa, M; De Cavanaugh, EM; Ferder, L; Inserra, F; Stella, I; Toblli, JE, 2002)
"Cardiac iron deposition may be involved in the development of cardiac fibrosis induced by angiotensin II."3.71Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. ( Ishizaka, N; Mitani, H; Mori, I; Nagai, R; Ohno, M; Saito, K; Sata, M; Usui, S; Yamazaki, I, 2002)
"To investigate the different effects of an angiotensin II type 1 (AT(1)) receptor antagonist, losartan, and an angiotensin converting enzyme (ACE) inhibitor, fosinopril, on cardiomyocyte apoptosis, myocardial fibrosis, and angiotensin II (Ang II) in the left ventricle of spontaneously hypertensive rats (SHRs)."3.71Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. ( Liang, X; Sun, M; Xie, X; Yang, T; Yu, G; Zhao, S, 2002)
"To investigate effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in the spontaneously hypertensive rats (SHR)."3.71[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats]. ( He, BX; Liang, XQ; Yu, GL, 2001)
"We randomized 24 adult cardiac troponin T (cTnT-Q(92)) mice, which exhibit myocyte disarray and interstitial fibrosis, to treatment with losartan or placebo and included 12 nontransgenic mice as controls."3.71Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. ( Bachireddy, P; Entman, M; Evans, A; Lim, DS; Lutucuta, S; Marian, AJ; Roberts, R; Youker, K, 2001)
"Compared with the fibrosis in rats of the model group, rats treated with either enalapril or losartan, or a combination of two drugs, showed a limited expansion of the interstitium (P < 0."3.71The expression of AT1 receptor on hepatic stellate cells in rat fibrosis induced by CCl4. ( Huang, X; Li, D; Lu, H; Wang, Z; Wei, H; Zhan, Y, 2001)
" The effect of the angiotensin II type 1 receptor antagonist, losartan (10 mg x kg(-1) x d(-1))on aldosterone-induced cardiac hypertrophy was also studied."3.71Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. ( Demura, M; Mabuchi, H; Takeda, Y; Usukura, M; Yoneda, T, 2002)
"In cirrhotic patients without ascites, creatinine clearance, 24-h urinary sodium excretion, and fractional excretion of sodium were significantly increased after losartan administration."3.71One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites. ( Chang, FY; Hou, MC; Lee, FY; Lee, SD; Lee, WC; Lin, HC; Yang, YY, 2002)
" To determine if the TI injury accompanying cyclosporine A (CsA) nephropathy was associated with accelerated apoptosis and ischemia, we treated rats for five weeks with CsA with or without losartan (to block angiotensin II type 1 receptor), or hydralazine/furosemide (H/F) (protocol #1)."3.70Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. ( Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE, 1998)
"Angiotensin II (Ang II) has been shown to be implicated in the development of renal fibrosis in several forms of chronic glomerulonephritides, but the precise mechanisms of its effects remain unclear."3.70Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. ( Cerullo, G; Colucci, M; Gesualdo, L; Grandaliano, G; Monno, R; Ranieri, E; Rossiello, MR; Schena, FP; Semeraro, N; Ursi, M, 1999)
"Animals were divided into three groups: myocarditis, myocarditis intervened by Losartan, and normal control."3.70[Preventional intervention of myocardial interstitial fibrosis in murine myocardium with acute myocarditis]. ( Cheng, X; Jing, Z; Yang, Y, 1998)
"In this study we infused phenylephrine into adult Wistar rats and used losartan to test for a possible role of angiotensin II in the phenylephrine-induced fibrosis."3.69Effect of angiotensin II blockade on the fibroproliferative response to phenylephrine in the rat heart. ( Brecher, P; Chobanian, AV; Crawford, DC; Farivar, RS, 1995)
"There was (1) low angiotensin receptor binding in normal myocardium; (2) markedly increased angiotensin II receptor binding at the site of left ventricular myocardial infarction and endocardial fibrosis of the interventricular septum at day 3 and weeks 1, 2, 4, and 8; (3) high angiotensin II receptor binding in the pericardial fibrosis that followed pericardiotomy, and in the fibrosis that appeared in response to suture insertion around the left coronary artery, in both infarcted and sham operated rats; (4) total displacement of normal and connective tissue angiotensin II receptor binding by DuP753, but not by PD123177; (5) ACE inhibition by lisinopril, but no change in angiotensin II receptor binding, at all sites of fibrosis; and (6) significant attenuation by lisinopril of collagen formation in the visceral pericardium of sham operated controls."3.69Angiotensin II receptor binding following myocardial infarction in the rat. ( Sun, Y; Weber, KT, 1994)
" Therefore, we investigated the effect of AT1 or AT2 subtype receptor chronic blockade by losartan or PD123319 on the vascular hypertrophy in rats with Ang II-induced hypertension."3.69Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. ( Benessiano, J; Caputo, L; Duriez, M; Henrion, D; Heymes, C; Levy, BI; Poitevin, P; Samuel, JL, 1996)
"Losartan is an angiotensin II receptor blocker (ARB) that impedes transforming growth factor (TGF) beta signaling by inhibiting activation of signal transduction molecule extracellular signal-regulated kinase (ERK)."3.01Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders. ( Wilson, SE, 2023)
"Treatment with losartan was safe, suggesting that it can be used for other indications in patients with hypertrophic cardiomyopathy, irrespective of obstructive physiology."2.80Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. ( Ahtarovski, K; Axelsson, A; Bundgaard, H; Corell, P; Havndrup, O; Ho, C; Iversen, K; Jensen, M; Langhoff, L; Norsk, J; Vejlstrup, N, 2015)
"In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis."2.71Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004)
"Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)."2.71Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005)
"Treatment with losartan (50 mg) was introduced."2.69Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. ( Campistol, JM; Clesca, PH; Iñigo, P; Jimenez, W; Lario, S; Oppenheimer, F; Rivera, F, 1999)
"Transforming growth factor beta 1 is a key molecule in the development of postoperative fibrosis."2.58Potential Usefulness of Losartan as an Antifibrotic Agent and Adjunct to Platelet-Rich Plasma Therapy to Improve Muscle Healing and Cartilage Repair and Prevent Adhesion Formation. ( Bolia, I; Briggs, K; Huard, J; Lowe, WR; Philippon, MJ; Utsunomiya, H, 2018)
"Rotator cuff repair combined with oral losartan and BMS of the greater tuberosity showed improved pullout strength and a highly organized tendon matrix in this rabbit chronic injury model."1.91Losartan in Combination With Bone Marrow Stimulation Showed Synergistic Effects on Load to Failure and Tendon Matrix Organization in a Rabbit Model. ( Altintas, B; Dornan, G; Fukase, N; Gao, X; Huard, J; Kashyap, R; Lacheta, L; Miles, JW; Millett, PJ; Murata, Y; Philippon, M; Ravuri, S; Tashman, S; Utsunomiya, H, 2023)
"Losartan is a typical Angiotensin II (ANG II) receptor antagonist and relaxes blood vessels."1.72Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. ( Ma, Y; Yu, R; Zhou, X; Zou, J, 2022)
"Cardiac fibrosis is a severe condition with limited therapeutic options and often occurs in chronic cardiovascular diseases such as hypertension and myocardial infarction."1.72Integrin subunit β-like 1 mediates angiotensin II-induced myocardial fibrosis by regulating the forkhead box Q1/Snail axis. ( Chen, W; Han, L; Ji, H; Yu, L; Zhu, H, 2022)
"Losartan is an inhibitor of transforming growth factor-β signaling."1.72Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. ( Ambrósio, R; Bandeira, F; Pereira-Souza, AL; Salomão, MQ; Souza Lima, A; Wilson, SE, 2022)
"Pleural fibrosis is associated with various inflammatory processes such as tuberculous pleurisy and bacterial empyema."1.48Inhibition of angiotensin II and calpain attenuates pleural fibrosis. ( Greer, PA; Huang, H; Ma, WL; Shi, HZ; Song, LJ; Su, Y; Xiang, F; Xin, JB; Xiong, L; Xu, JJ; Yang, J; Ye, H; Yu, F, 2018)
"Losartan treatment for three weeks lowered systolic blood pressure in both Control and Restricted groups but this difference was not sustained after the cessation of treatment."1.48Angiotensin receptor blockade in juvenile male rat offspring: Implications for long-term cardio-renal health. ( Gallo, LA; Mazzuca, MQ; Moritz, KM; Parkington, HC; Tare, M; Walton, SL; Wlodek, ME, 2018)
"Treatment with losartan reduced left ventricular dysfunction and prevented increased extracellular volume fraction, indicating that T1 mapping is sensitive to pharmacological prevention of fibrosis."1.40T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy. ( Fiedler, LR; Gsell, W; Habib, J; McSweeney, SJ; Prasad, SK; Price, AN; Schneider, MD; Stuckey, DJ; Thin, MZ, 2014)
"Losartan treatment partially attenuated these responses."1.40Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. ( He, P; Li, D; Zhang, B, 2014)
"Losartan is a Food and Drug Administration approved antihypertensive medication that is recently emerging as an antifibrotic therapy."1.40Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. ( Corona, BT; Garg, K; Walters, TJ, 2014)
"AKF-PD was used to treat renal fibrosis in unilateral ureteral obstruction (UUO) obstructive nephropathy in rats."1.39Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. ( Cheng, GJ; Hu, GY; Huang, L; Mei, WJ; Peng, ZZ; Qin, J; Tao, LJ; Xie, YY; Yuan, QJ; Yuan, XN, 2013)
"Losartan treatment reduced the fibrosis in the CC UUO kidneys."1.38Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. ( Brazin, JA; Chen, J; Estephan, R; Felsen, D; Kameue, T; Maack, T; Mora, R; O'Connor, N; Poppas, DP; Reid, AC; Seshan, SV; Silver, RB; Veerappan, A, 2012)
"Recent studies showed that chronic administration of losartan, an angiotensin II type I receptor antagonist, improved skeletal muscle function in dystrophin-deficient mdx mice."1.37Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. ( Gordish-Dressman, H; Guerron, AD; Hoffman, EP; Iantorno, M; Nagaraju, K; Rayavarapu, S; Sali, A; Spurney, CF; van der Meulen, J; Yu, Q, 2011)
"Fibrosis was evaluated in the diaphragm and heart by Trichrome stain and by determination of tissue hydroxyproline content."1.37Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. ( Acosta, P; Barton, ER; Bish, LT; Gazzara, JA; Morine, KJ; Sleeper, MM; Sweeney, HL; Yarchoan, M, 2011)
"Fibrosis was accompanied by activation of pancreatic stellate cells (PSC) evaluated by Western blot analysis for alpha-smooth muscle actin."1.36Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. ( Neuschwander-Tetri, BA; Oshima, K; Talkad, V; Ulmasov, B; Xu, Z, 2010)
"Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart."1.36Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010)
"Losartan treatment reduced the mortality of TG: Mean life span was raised from 116 to 193 days (n = 18 end, p < 0."1.36Losartan reduces mortality in a genetic model of heart failure. ( Baba, HA; Gergs, U; Grossmann, C; Günther, S; Hauptmann, S; Holzhausen, HJ; Jones, LR; Kusche, T; Neumann, J; Punkt, K, 2010)
"Losartan treatment did not reverse pathologic remodeling of established HCM but did reduce non-myocyte proliferation."1.36Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. ( Alcalai, R; Eminaga, S; Gorham, JM; Hoffman, SR; Kim, JB; Konno, T; Markwald, RR; Molkentin, JD; Nayor, M; Norris, RA; Schmitt, JP; Seidman, CE; Seidman, JG; Tager, AM; Teekakirikul, P; Toka, O; Wakimoto, H; Wang, L; Wolf, CM, 2010)
"Losartan treatment resulted in improvement of myocardial function and suppressed cardiac and renal fibrosis compared with the diabetic group."1.35Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. ( Aizawa, Y; Arozal, W; Kodama, M; Ma, M; Suzuki, K; Tachikawa, H; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K, 2009)
"RV hypertrophy was also prevented, but LV hypertrophy only partially, and kidney hypertrophy not at all."1.35Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats. ( Leenen, FH; Liang, B, 2008)
"Diabetic nephropathy is the main cause of end-stage renal disease."1.34Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice. ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2007)
"Aldosterone plays a key role in the pathogenesis of Ang II-induced organ damage."1.33Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. ( Al-Saadi, N; Dechend, R; Fiebeler, A; Hilfenhaus, G; Jeng, AY; Luft, FC; Maser-Gluth, C; Meiners, S; Muller, DN; Nussberger, J; Rong, S; Shagdarsuren, E; Webb, RL; Wellner, M, 2005)
"Renal fibrosis was evaluated through TGFbeta expression and superoxide dismutase (SOD) activity, hydroxyl radicals, O2- and total antioxidant activity were measured by spectrophotometric assay."1.33Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP 70) expression in obstructive nephropathy. ( Carrizo, L; Manucha, W; Molina, H; Ruete, C; Vallés, P, 2005)
" Corresponding dosage of Losartan can also alleviate the motion capability and type I collagen content of hPSCs compared with AngII treatment and non-treatment control groups."1.33Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells. ( Liu, WB; Wang, XP; Wu, K; Zhang, RL, 2005)
"Losartan pretreated-rats presented diminished FN abundance in homogenates of cortex tissue from ischemic rats with or without reperfusion."1.32Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function. ( Barrilli, A; Elías, MM; Menacho, M; Molinas, S; Petrini, G, 2004)
"Tubulointerstitial fibrosis is considered to be common endpoint result of many forms of chronic renal diseases."1.31Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. ( Dai, C; Liu, Y; Yang, J, 2002)
"Compared with WKY, SHR exhibited left ventricular hypertrophy, increased (P<0."1.31Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. ( Díez, J; Etayo, JC; Iraburu, MJ; López, B; Varela, M; Varo, N, 2000)
"Aldosterone levels were not significantly elevated, suggesting direct proliferative effects of Ang II."1.30Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. ( Gray, GA; Kenyon, CJ; McEwan, PE; Sherry, L; Webb, DJ, 1998)
" This dose of losartan shifted the in vivo dose-response curve of the angiotensin II-induced elevation of left ventricular systolic pressure (LVSP) to the right."1.30Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats. ( Baba, HA; Bauer, M; Irlbeck, M; Iwai, T; Schmid, KW; Zimmer, HG, 1999)
"Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure."1.29Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995)

Research

Studies (183)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's16 (8.74)18.2507
2000's58 (31.69)29.6817
2010's74 (40.44)24.3611
2020's35 (19.13)2.80

Authors

AuthorsStudies
Toba, H1
Ikemoto, MJ1
Kobara, M1
Nakata, T1
Castoldi, G2
Carletti, R2
Ippolito, S1
Stella, A2
Zerbini, G2
Pelucchi, S1
Zatti, G1
di Gioia, CRT1
Sampaio, LP4
Hilgert, GSL4
Shiju, TM4
Murillo, SE1
Santhiago, MR4
Wilson, SE6
Askaripour, M1
Najafipour, H1
Saberi, S1
Jafari, E1
Rajabi, S1
Kuźmiuk-Glembin, I1
Heleniak, Z1
Pięta, R1
Głyda, M1
Lizakowski, S1
Renke, M1
Konopa, J1
Chamienia, A2
Biedunkiewicz, B2
Rutkowski, B2
Tylicki, L2
Dębska-Ślizień, A1
Dorotea, D2
Jiang, S2
Pak, ES1
Son, JB1
Choi, HG1
Ahn, SM1
Ha, H2
Feng, R1
Wan, J1
He, Y3
Gong, H1
Xu, Z2
Feng, J1
Zou, J1
Zhou, X1
Ma, Y2
Yu, R1
Zhu, H1
Ji, H1
Chen, W1
Han, L1
Yu, L1
Pereira-Souza, AL1
Ambrósio, R1
Bandeira, F1
Salomão, MQ1
Souza Lima, A1
Sriwatananukulkit, O2
Desclaux, S2
Tawonsawatruk, T2
Srikuea, R2
Himakhun, W2
Likitnukul, S2
Hemstapat, R2
Motherwell, JM1
Dolan, CP1
Kanovka, SS1
Edwards, JB1
Franco, SR1
Janakiram, NB1
Valerio, MS1
Goldman, SM1
Dearth, CL1
Khazaeli, M1
Nunes, ACF1
Zhao, Y1
Khazaali, M1
Prudente, J1
Vaziri, ND1
Singh, B1
Lau, WL1
Liu, B1
Jie, X1
Deng, J1
Zhang, S1
Lu, F1
Liu, X3
Zhang, D1
Martínez-Arias, L1
Fernández-Villabrille, S1
Alonso-Montes, C1
García-Navazo, G1
Ruíz-Torres, MP1
Alajarín, R1
Alvarez-Builla, J1
Gutiérrez-Calabres, E1
Vaquero-López, JJ1
Carrillo-López, N1
Rodríguez-Puyol, D1
Cannata-Andía, JB1
Panizo, S1
Naves-Díaz, M1
Lacheta, L1
Gao, X4
Miles, JW1
Murata, Y1
Fukase, N1
Utsunomiya, H3
Dornan, G1
Tashman, S1
Kashyap, R1
Altintas, B1
Ravuri, S2
Philippon, M1
Huard, J4
Millett, PJ1
Wei, X1
Jin, J1
Wu, J1
Guo, J2
Yang, Z1
Chen, L1
Hu, K1
Li, L2
Jia, M1
Li, Q2
Lv, X1
Ge, F1
Ma, S1
Wu, H1
Zhi, X1
Wang, X1
Jiang, L1
Osto, E1
Zhang, J2
Meng, D1
Huang, Z1
Nie, H1
Liu, G1
Li, P2
Peng, YH1
Xiao, J1
Gu, W1
Li, TS1
Song, J1
Xia, Y1
Yan, X1
Luo, J1
Jiang, C1
Zhang, M2
Shi, GP1
Zhu, W1
Eslahi, A1
Shirazi, M1
Khoshnood, O1
Noorafshan, A1
Karbalay-Doust, S1
Baranowski, A1
Schlemmer, L1
Förster, K1
Slotina, E1
Mickan, T1
Truffel, S1
Klein, A1
Mattyasovszky, SG1
Hofmann, A1
Ritz, U1
Rommens, PM1
Tawfik, VL1
Quarta, M1
Paine, P1
Forman, TE1
Pajarinen, J1
Takemura, Y1
Goodman, SB1
Rando, TA2
Clark, JD1
da Silva-Bertani, DCT1
Vileigas, DF1
Mota, GAF1
de Souza, SLB1
Sant'Ana, PG1
Freire, PP1
de Tomasi, LC1
Corrêa, CR1
Padovani, CR1
Fernandes, T1
de Oliveira, EM1
Cicogna, AC1
Li, S2
Li, Y2
Zhang, Y4
Jin, F1
Wei, Z1
Yang, Y2
Mao, N1
Ge, X1
Xu, H1
Yang, F1
Nakama, GY1
Gonzalez, S1
Matre, P1
Mu, X1
Whitney, KE1
Arner, JW1
Philippon, MJ2
Oh, DS1
Son, E1
Kim, DS1
Baker, JV1
Wolfson, J1
Collins, G1
Morse, C1
Rhame, F1
Liappis, AP1
Rizza, S1
Temesgen, Z1
Mystakelis, H1
Deeks, S1
Neaton, J1
Schacker, T1
Sereti, I1
Tracy, RP1
He, YL1
Wen, JG1
Pu, QS1
Wen, YB1
Zhai, RQ1
Chen, Y2
Liu, EP1
Xing, D1
Ji, FP1
Yang, XH1
Wang, QW1
Wang, Y6
Bauer, SB1
Akazawa, Y1
Fujioka, T1
Ide, H1
Yazaki, K1
Honjo, O2
Sun, M3
Friedberg, MK2
Wang, EY1
Kuzmanov, U1
Smith, JB1
Dou, W1
Rafatian, N1
Lai, BFL1
Lu, RXZ1
Wu, Q1
Yazbeck, J1
Zhang, XO1
Sun, Y4
Gramolini, A1
Radisic, M1
Leite, APO1
Li, XC1
Hassan, R1
Zheng, X1
Alexander, B1
Casarini, DE2
Zhuo, JL1
Torres, B1
Guardo, AC1
Squarcia, M1
Diaz, A1
Fabra, A1
Caballero, M1
Ugarte, A1
Leal, L1
Gatell, JM1
Plana, M1
Garcia, F1
García-Martín, A1
Navarrete, C1
Garrido-Rodríguez, M1
Prados, ME1
Caprioglio, D1
Appendino, G1
Muñoz, E1
Awazu, M1
Yamada, M1
Asada, N1
Hashiguchi, A1
Kosaki, K1
Matsumura, K1
McPherson, S1
Wilkinson, N1
Tiniakos, D1
Wilkinson, J1
Burt, AD1
McColl, E1
Stocken, DD1
Steen, N1
Barnes, J1
Goudie, N1
Stewart, S1
Bury, Y1
Mann, D1
Anstee, QM1
Day, CP1
Li, WJ1
Xu, M1
Gu, M1
Zheng, DC1
Cai, Z1
Wang, Z2
Bartko, PE1
Dal-Bianco, JP1
Guerrero, JL1
Beaudoin, J1
Szymanski, C1
Kim, DH1
Seybolt, MM1
Handschumacher, MD1
Sullivan, S1
Garcia, ML1
Titus, JS1
Wylie-Sears, J1
Irvin, WS1
Messas, E1
Hagège, AA1
Carpentier, A1
Aikawa, E1
Bischoff, J1
Levine, RA1
Song, LJ1
Xiang, F1
Ye, H1
Huang, H1
Yang, J2
Yu, F1
Xiong, L1
Xu, JJ1
Greer, PA1
Shi, HZ1
Xin, JB1
Su, Y1
Ma, WL1
Gu, X1
Xu, D1
Fu, L1
Mei, C1
Nelson, JW1
Ferdaus, MZ1
McCormick, JA1
Minnier, J1
Kaul, S1
Ellison, DH1
Barnes, AP1
Ongali, B1
Nicolakakis, N1
Tong, XK1
Lecrux, C1
Imboden, H1
Hamel, E1
Walton, SL1
Mazzuca, MQ1
Tare, M1
Parkington, HC1
Wlodek, ME1
Moritz, KM1
Gallo, LA1
Hosseinian, S1
Ebrahimzadeh Bideskan, A1
Shafei, MN1
Sadeghnia, HR1
Soukhtanloo, M1
Shahraki, S1
Samadi Noshahr, Z1
Khajavi Rad, A1
Bolia, I1
Briggs, K1
Lowe, WR1
Koszegi, S1
Molnar, A1
Lenart, L1
Hodrea, J1
Balogh, DB1
Lakat, T1
Szkibinszkij, E1
Hosszu, A1
Sparding, N1
Genovese, F1
Wagner, L1
Vannay, A1
Szabo, AJ1
Fekete, A1
Leenen, FHH1
Ahmad, M1
Marc, Y1
Llorens-Cortes, C1
Nafar, M1
Samavat, S1
Shahraki, E1
Choi, JA1
Kim, JE1
Ju, HH1
Lee, J1
Jee, D1
Park, CK1
Paik, SY1
Poletto Bonetto, JH1
Fernandes, RO1
Dartora, DR1
Flahault, A1
Sonea, A1
Cloutier, A1
Belló-Klein, A1
Nuyt, AM1
Kusunoki, H1
Taniyama, Y1
Rakugi, H1
Morishita, R1
Kim, HS1
No, CW1
Goo, SH1
Cha, TJ1
Cho, MY2
Li, J1
Assad, RS1
Rohailla, S1
Apitz, C1
Redington, AN1
Qin, J1
Xie, YY1
Huang, L1
Yuan, QJ1
Mei, WJ1
Yuan, XN1
Hu, GY1
Cheng, GJ1
Tao, LJ1
Peng, ZZ1
Issa, N1
Ortiz, F1
Reule, SA1
Kukla, A1
Kasiske, BL1
Mauer, M2
Jackson, S2
Matas, AJ1
Ibrahim, HN2
Najafian, B2
Stuckey, DJ1
McSweeney, SJ1
Thin, MZ1
Habib, J1
Price, AN1
Fiedler, LR1
Gsell, W1
Prasad, SK1
Schneider, MD1
Arnoni, CP1
Maquigussa, E1
Passos, CS1
Pereira, LG1
Boim, MA1
Shimada, YJ1
Passeri, JJ1
Baggish, AL1
O'Callaghan, C1
Lowry, PA1
Yannekis, G1
Abbara, S1
Ghoshhajra, BB1
Rothman, RD1
Ho, CY1
Januzzi, JL1
Seidman, CE2
Fifer, MA1
He, P1
Li, D2
Zhang, B1
Rosendahl, A1
Niemann, G1
Lange, S1
Ahadzadeh, E1
Krebs, C1
Contrepas, A1
van Goor, H1
Wiech, T1
Bader, M1
Schwake, M1
Peters, J1
Stahl, R1
Nguyen, G1
Wenzel, UO1
di Gioia, CR1
Bombardi, C1
Maestroni, S1
Steckelings, UM1
Dahlöf, B2
Unger, T1
Garg, K1
Corona, BT1
Walters, TJ1
Axelsson, A1
Iversen, K1
Vejlstrup, N1
Ho, C1
Norsk, J1
Langhoff, L1
Ahtarovski, K1
Corell, P1
Havndrup, O1
Jensen, M1
Bundgaard, H1
Díaz-Piña, G1
Montes, E1
Checa, M1
Becerril, C1
García de Alba, C1
Vega, A1
Páramo, I1
Ordoñez-Razo, R1
Ruiz, V1
Afroze, SH1
Munshi, MK1
Martínez, AK1
Uddin, M1
Gergely, M1
Szynkarski, C1
Guerrier, M1
Nizamutdinov, D1
Dostal, D1
Glaser, S1
Zhao, LM1
Wang, LP1
Wang, HF1
Ma, XZ1
Zhou, DX1
Deng, XL1
Chen, XQ1
Zhang, DL1
Zhang, MJ1
Guo, M2
Zhan, YY1
Liu, F1
Jiang, WF2
Zhou, L2
Zhao, L1
Wang, QX2
Mohapatra, A1
Matthai, SM1
Vijayakumar, K1
Basu, G1
Mehrotra, P1
Patel, JB1
Ivancic, CM1
Collett, JA1
Basile, DP1
Vohra, R1
Accorsi, A1
Kumar, A1
Walter, G1
Girgenrath, M1
Hao, G1
Han, Z1
Meng, Z1
Wei, J1
Gao, D1
Zhang, H1
Wang, N1
DeLeon-Pennell, KY1
de Jong, MA1
Mirkovic, K1
Mencke, R1
Hoenderop, JG1
Bindels, RJ1
Vervloet, MG1
Hillebrands, JL1
van den Born, J1
Navis, G1
de Borst, MH1
Fang, J1
Wang, W1
Sun, S1
Lu, X1
Qiu, M1
Liu, Q1
Lu, D2
Wang, S2
Wang, K2
Zhang, Q1
Fang, P1
Li, Z1
Geng, J1
Shan, Q1
Wang, TJ1
Lian, GL1
Lin, X1
Zhong, HB1
Xu, CS1
Wang, HJ1
Xie, LD1
Miguel-Carrasco, JL1
Beaumont, J2
San José, G1
Moreno, MU1
López, B3
González, A1
Zalba, G2
Díez, J5
Fortuño, A1
Ravassa, S1
Oosterhuis, NR1
Bongartz, LG1
Verhaar, MC1
Cheng, C1
Xu, YJ1
van Koppen, A1
Cramer, MJ1
Goldschmeding, R1
Gaillard, CA1
Doevendans, PA1
Braam, B1
Joles, JA2
Bedair, HS1
Karthikeyan, T1
Quintero, A1
Matsuhisa, S1
Otani, H1
Okazaki, T1
Yamashita, K1
Akita, Y1
Sato, D1
Moriguchi, A1
Iwasaka, T3
Wu, ZL1
Xu, DL1
Deng, LH1
Wen, YW1
Huang, P1
Bai, SC1
Su, L1
van den Borne, SW1
Isobe, S1
Zandbergen, HR1
Petrov, A1
Wong, ND1
Fujimoto, S1
Fujimoto, A1
Lovhaug, D1
Smits, JF1
Daemen, MJ1
Blankesteijn, WM1
Reutelingsperger, C1
Zannad, F1
Narula, N1
Vannan, MA1
Pitt, B1
Hofstra, L1
Narula, J1
Canguven, O1
Lagoda, G1
Sezen, SF1
Burnett, AL1
Jessup, JA1
Westwood, BM1
Chappell, MC1
Groban, L1
Deb, DK2
Kong, J2
Ning, G1
Li, G1
Zhang, Z1
Strugnell, S1
Sabbagh, Y1
Arbeeny, C1
Li, YC2
Inserra, F2
Basso, N2
Ferder, M1
Userpater, M1
Stella, I2
Paglia, N1
Inserra, P1
Tenembaum, D1
Ferder, L2
Desbuards, N1
Hyvelin, JM1
Machet, MC2
Eder, V2
Garrigue, MA1
Halimi, JM1
Antier, D1
Arozal, W1
Watanabe, K1
Veeraveedu, PT1
Ma, M1
Thandavarayan, RA1
Suzuki, K1
Tachikawa, H1
Kodama, M1
Aizawa, Y1
Naito, T1
Ma, LJ1
Yang, H2
Zuo, Y1
Tang, Y1
Han, JY1
Kon, V1
Fogo, AB1
Chang, A1
Ulmasov, B1
Talkad, V1
Oshima, K1
Neuschwander-Tetri, BA1
Stein, M1
Boulaksil, M1
Jansen, JA1
Herold, E1
Noorman, M1
van Veen, TA1
Houtman, MJ1
Engelen, MA1
Hauer, RN1
de Bakker, JM1
van Rijen, HV1
Günther, S1
Baba, HA2
Hauptmann, S1
Holzhausen, HJ1
Grossmann, C1
Punkt, K1
Kusche, T1
Jones, LR1
Gergs, U1
Neumann, J1
Ferreira, DN1
Katayama, IA1
Oliveira, IB1
Rosa, KT1
Furukawa, LN1
Coelho, MS1
Heimann, JC1
Teekakirikul, P1
Eminaga, S1
Toka, O1
Alcalai, R1
Wang, L1
Wakimoto, H1
Nayor, M1
Konno, T1
Gorham, JM1
Wolf, CM1
Kim, JB1
Schmitt, JP1
Molkentin, JD1
Norris, RA1
Tager, AM1
Hoffman, SR1
Markwald, RR1
Seidman, JG1
He, X1
Peng, L1
Zhu, Y1
Ma, H1
Lin, J1
Duan, DD1
Spurney, CF1
Sali, A1
Guerron, AD1
Iantorno, M1
Yu, Q1
Gordish-Dressman, H1
Rayavarapu, S1
van der Meulen, J1
Hoffman, EP1
Nagaraju, K1
Fan, D1
Wang, C1
Wang, JY1
Cui, XB1
Wu, D1
Zhou, Y1
Wu, LL1
Worou, ME1
Belmokhtar, K1
Bonnet, P1
Vourc'h, P1
Khamis, G1
Bish, LT1
Yarchoan, M1
Sleeper, MM1
Gazzara, JA1
Morine, KJ1
Acosta, P1
Barton, ER1
Sweeney, HL1
Fogari, R1
Mugellini, A1
Destro, M1
Corradi, L1
Lazzari, P1
Zoppi, A1
Preti, P1
Derosa, G1
Huang, YY1
Xu, AP1
Zhou, SS1
Fu, JZ1
Du, H1
Veerappan, A1
Reid, AC1
O'Connor, N1
Mora, R1
Brazin, JA1
Estephan, R1
Kameue, T1
Chen, J2
Felsen, D2
Seshan, SV2
Poppas, DP1
Maack, T1
Silver, RB1
Rehman, A1
Leibowitz, A1
Yamamoto, N1
Rautureau, Y1
Paradis, P1
Schiffrin, EL2
Wengrower, D1
Zanninelli, G1
Latella, G1
Necozione, S1
Metanes, I1
Israeli, E1
Lysy, J1
Pines, M1
Papo, O1
Goldin, E1
Xie, XS1
Zuo, C1
Zhang, ZY1
Liu, HC1
Feng, SG1
Zhang, CL1
Yuan, W1
Fan, JM1
Sun, CY1
Chang, SC1
Wu, MS1
Park, JK1
Ki, MR1
Lee, EM1
Kim, AY1
You, SY1
Han, SY1
Lee, EJ1
Hong, IH1
Kwon, SH1
Kim, SJ1
Jeong, KS1
Gu, J1
Tan, HW1
Meems, LM1
Cannon, MV1
Mahmud, H1
Voors, AA1
van Gilst, WH1
Silljé, HH1
Ruifrok, WP1
de Boer, RA1
Moilanen, AM1
Rysä, J1
Serpi, R1
Mustonen, E1
Szabò, Z1
Aro, J1
Näpänkangas, J1
Tenhunen, O1
Sutinen, M1
Salo, T1
Ruskoaho, H1
MacDonald, EM1
Cohn, RD1
Geirsson, A1
Singh, M1
Ali, R1
Abbas, H1
Li, W1
Sanchez, JA1
Hashim, S1
Tellides, G1
Parlakgumus, A1
Colakoglu, T1
Kayaselcuk, F1
Colakoglu, S1
Ezer, A1
Calıskan, K1
Karakaya, J1
Yildirim, S1
Fu, W1
Jin, Z1
Wang, H2
Cheng, W1
Zhou, H1
Yin, P1
Peng, W1
Connaire, J1
Matas, A1
Ney, A1
West, A1
Lentsch, N1
Ericksen, J1
Bodner, J1
Kasiske, B1
Gay-Jordi, G1
Guash, E1
Benito, B1
Brugada, J1
Nattel, S1
Mont, L1
Serrano-Mollar, A1
Dai, C1
Liu, Y1
Toblli, JE1
De Cavanaugh, EM1
Angerosa, M1
Ishizaka, N2
Saito, K2
Mitani, H1
Yamazaki, I1
Sata, M1
Usui, S1
Mori, I1
Ohno, M1
Nagai, R2
Shibasaki, Y2
Nishiue, T2
Masaki, H2
Matsubara, H2
Yu, G1
Liang, X1
Xie, X1
Yang, T1
Zhao, S1
Peng, J1
Gurantz, D1
Tran, V1
Cowling, RT1
Greenberg, BH1
He, BX1
Yu, GL1
Liang, XQ1
Yang, CW3
Ahn, HJ2
Kim, WY2
Li, C2
Jung, JY1
Yoon, SA1
Kim, YS3
Cha, JH2
Kim, J3
Bang, BK2
Rupérez, M1
Lorenzo, O1
Blanco-Colio, LM1
Esteban, V1
Egido, J1
Ruiz-Ortega, M1
Tang, X1
Shiraishi, K1
Yoshida, K1
Fujimiya, T1
Naito, K1
González, GE1
Mangas, F1
Palleiro, J1
Rodríguez, M1
Depetris Chauvin, A1
Gelpi, RJ1
Morales, C1
Manucha, W2
Oliveros, L1
Carrizo, L2
Seltzer, A1
Vallés, P2
Barrilli, A1
Molinas, S1
Petrini, G1
Menacho, M1
Elías, MM1
Iglarz, M1
Touyz, RM1
Viel, EC1
Amiri, F1
Ciulla, MM1
Paliotti, R1
Esposito, A1
Nicholls, MG1
Smith, RD1
Gilles, L1
Magrini, F1
Zanchetti, A1
Uesugi, T1
Froh, M1
Gäbele, E1
Isayama, F1
Bradford, BU1
Ikai, I1
Yamaoka, Y1
Arteel, GE1
Asbun, J1
Manso, AM1
Villarreal, FJ1
Gröholm, T1
Finckenberg, P1
Palojoki, E1
Saraste, A1
Bäcklund, T1
Eriksson, A1
Laine, M1
Mervaala, E1
Tikkanen, I1
Wang, XP2
Zhang, R1
Wu, K2
Wu, L1
Dong, Y1
Bos, R1
Mougenot, N1
Findji, L1
Médiani, O1
Vanhoutte, PM1
Lechat, P1
Fiebeler, A1
Nussberger, J1
Shagdarsuren, E1
Rong, S1
Hilfenhaus, G1
Al-Saadi, N1
Dechend, R1
Wellner, M1
Meiners, S1
Maser-Gluth, C1
Jeng, AY1
Webb, RL1
Luft, FC1
Muller, DN1
Sun, BK1
Lim, SW1
Song, JC1
Kang, SW1
Kang, DH1
Ruete, C1
Molina, H1
Liu, WB1
Zhang, RL1
Tamura, K1
Matsumoto, N1
Mori, Y1
Nishikawa, M1
Sugaru, E2
Nakagawa, T2
Ono-Kishino, M2
Nagamine, J2
Tokunaga, T2
Kitoh, M2
Hume, WE2
Nagata, R2
Taiji, M2
Kellner, D1
Richardson, I1
El Chaar, M1
Vaughan, ED1
Poppas, D1
Christensen, MK1
Olsen, MH1
Wachtell, K1
Tuxen, C1
Fossum, E1
Bang, LE1
Wiinberg, N1
Devereux, RB1
Kjeldsen, SE1
Hildebrandt, P1
Rokkedal, J1
Ibsen, H1
Ishikawa, A1
Tanaka, M1
Ohta, N1
Ozono, S1
Kitamura, T1
Wojnarowski, K1
Zdrojewski, Z1
Aleksandrowicz, E1
Lysiak-Szydlowska, W1
De Mello, WC1
Specht, P1
Park, DH1
Baik, SK1
Choi, YH1
Kim, MY1
Rhim, DW1
Kim, JW1
Kwon, SO1
Kim, CH1
Ahn, SC1
Bahk, TJ1
Daniels, MD1
Leon, JS1
Engman, DM1
Liang, B1
Leenen, FH1
Matsuzaki, G1
Furuta, K1
Hongo, M1
Sakurai, R1
Koike, K1
Ohtake, T1
Oka, M1
Maesato, K1
Mano, T1
Ikee, R1
Moriya, H1
Kobayashi, S1
Farivar, RS1
Crawford, DC1
Chobanian, AV1
Brecher, P1
Nicoletti, A1
Heudes, D1
Hinglais, N1
Appay, MD1
Philippe, M1
Sassy-Prigent, C1
Bariety, J1
Michel, JB1
Weber, KT2
Levy, BI1
Benessiano, J1
Henrion, D1
Caputo, L1
Heymes, C1
Duriez, M1
Poitevin, P1
Samuel, JL1
Young, MJ1
Funder, JW1
De Carvalho Frimm, C1
Thomas, SE1
Andoh, TF1
Pichler, RH1
Shankland, SJ1
Couser, WG1
Bennett, WM1
Johnson, RJ1
Zhang, JQ1
Ramires, FJ1
Peters, H1
Border, WA1
Noble, NA1
McEwan, PE1
Gray, GA1
Sherry, L1
Webb, DJ1
Kenyon, CJ1
Iwai, T1
Bauer, M1
Irlbeck, M1
Schmid, KW1
Zimmer, HG1
Varo, N2
Etayo, JC2
Iraburu, MJ2
Montiel, C1
Gil, MJ1
Monreal, I1
Gesualdo, L1
Ranieri, E1
Monno, R1
Rossiello, MR1
Colucci, M1
Semeraro, N1
Grandaliano, G1
Schena, FP1
Ursi, M1
Cerullo, G1
Campistol, JM1
Iñigo, P1
Jimenez, W1
Lario, S1
Clesca, PH1
Oppenheimer, F1
Rivera, F1
Reaves, PY1
Gelband, CH1
Berecek, KH1
Katovich, MJ1
Raizada, MK1
Varela, M1
Jing, Z1
Cheng, X1
Pinto, YM1
Pinto-Sietsma, SJ1
Philipp, T1
Engler, S1
Kossamehl, P1
Hocher, B1
Marquardt, H1
Sethmann, S1
Lauster, R1
Merker, HJ1
Paul, M1
González Bosc, L1
Kurnjek, ML1
Müller, A1
Lim, DS1
Lutucuta, S1
Bachireddy, P1
Youker, K1
Evans, A1
Entman, M1
Roberts, R1
Marian, AJ1
Shin, MJ1
Kim, SK1
Park, JH1
Kim, YO1
Wei, H1
Lu, H1
Zhan, Y1
Huang, X1
Takeda, Y1
Yoneda, T1
Demura, M1
Usukura, M1
Mabuchi, H1
Yang, YY1
Lin, HC1
Lee, WC1
Hou, MC1
Lee, FY1
Chang, FY1
Lee, SD1
Fukui, H1

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial[NCT02049307]Phase 2108 participants (Actual)Interventional2014-10-16Completed
A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216]Phase 240 participants (Anticipated)Interventional2023-08-17Recruiting
Angiotensin II Blockade for the Prevention of Cortical Interstitial Expansion and Graft Loss in Kidney Transplant Recipients[NCT00067990]Phase 4153 participants (Actual)Interventional2002-12-31Completed
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy[NCT01150461]Phase 220 participants (Actual)Interventional2007-02-28Completed
Clinical and Genetic Determinants of Disease Progression and Response to Lifestyle and Pharmacological Interventions in Patients With Hypertrophic Cardiomyopathy[NCT05366101]Phase 2/Phase 3168 participants (Actual)Interventional2019-04-01Completed
Clinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic Cardiomyopathy[NCT03832660]Phase 2168 participants (Actual)Interventional2019-05-03Completed
INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan.[NCT01447654]Phase 2130 participants (Actual)Interventional2011-11-30Completed
A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation[NCT05285878]Phase 220 participants (Anticipated)Interventional2022-07-28Enrolling by invitation
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260]Phase 3496 participants (Actual)Interventional1995-06-30Completed
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)[NCT03317925]29 participants (Actual)Observational2014-07-16Completed
Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124]Phase 3291 participants (Anticipated)Interventional2008-07-31Recruiting
Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060]Phase 453 participants (Actual)Interventional2007-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in CD4+ Cell Count From Baseline to 12 Months.

Change in cluster of differentiation 4 (CD4+) cell count from baseline to 12 months (NCT02049307)
Timeframe: Baseline and 12 months

InterventionCells/mm^3 (Mean)
Treatment (Losartan)15.1
Placebo6.8

Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 12 Months

Difference between treatment and control IL-6 plasma levels from pre-treatment to on-treatment values (NCT02049307)
Timeframe: Baseline and 12 months

Interventionpg/mL (Mean)
Treatment0.14
Placebo0.29

Doubling of Interstitium or Any ESRD

Doubling of the interstitial or any defined ESRD (including IF/TA) (NCT00067990)
Timeframe: Baseline to 5 years

InterventionParticipants (Count of Participants)
Losartan6
Placebo12

Number of Participants With Cortical Interstitial Volume Expansion or Any ESRD

Number of subjects who had doubling of the interstitial or any end stage renal disease (ESRD) not attributed to interstitial fibrosis and tubular atrophy (IF/TA) (NCT00067990)
Timeframe: Baseline and 5 Years Post Transplant

InterventionParticipants (Count of Participants)
Losartan7
Placebo15

Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging.

(NCT01150461)
Timeframe: Baseline and 1 year

InterventionPercentage change in fibrotic myocardium (Mean)
Losartan 50 mg PO BID-23
Placebo31

Percentage Change From Baseline in Left Ventricular Mass at 1 Year as Assessed by Magnetic Resonance Imaging.

(NCT01150461)
Timeframe: Baseline and 1 year

InterventionPercentage change in LV mass (Mean)
Losartan 50 mg PO BID-5
Placebo5

Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo.

Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

,
Interventionmicrograms/L (Mean)
Baseline (PINP)12 Months (PINP)Baseline (PIIINP)12 Months (PIIINP)Baseline (ICTP)12 Months (ICTP)
Placebo Control2.10.64.51.62.5-2.3
Spironolactone2.10.74.72.02.22.7

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Left Atrial Dimension (in mm)

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)

,
Interventionmillimeters (Mean)
Left Atrial Dimension (Baseline)Left Atrial Dimension (12-Month Follow-Up)
Placebo Control4140
Spironolactone4040

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Left Ventricular End-Diastolic (LVED) Cavity Size (in mm/m^2)

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)

,
Interventionmm/m^2 (Mean)
LVED Cavity Size (Baseline)LVED Cavity Size (12-Month Follow-Up)
Placebo Control145146
Spironolactone133129

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Maximum Left Ventricular Wall Thickness (in mm)

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

,
Interventionmillimeters (Mean)
Maximum Left Ventricular Wall Thickness (Baseline)Maximum Left Ventricular Wall Thickness (12-Month Follow-Up)
Placebo Control2119
Spironolactone2222

Assessment of Cardiac Mass and Fibrosis by Cardiac Magnetic Resonance Imaging (CMR) - Percentage of Left Ventricular Mass (%LV)

CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

,
InterventionPercentage of Total LV Mass (Mean)
LGE Assessment of Myocardial Fibrosis (Baseline)LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up)
Placebo Control2.52.8
Spironolactone1.11.8

Measure of Functional Capacity: Peak Oxygen Consumption With Exercise

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

,
Interventionml/kg/min (Mean)
Peak VO2 (Baseline)Peak VO2 (12-Month Follow-Up)
Placebo Control2829
Spironolactone3029

Measure of Heart Failure Symptoms According to the New York Heart Association Functional Class

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)

,
Interventionscore on a scale (Mean)
NYHA Class (Baseline)NYHA Class (12-Month Follow Up)
Placebo Control1.51.6
Spironolactone1.61.7

Measure of Indices of Diastolic Function by Tissue Doppler Echocardiography (Septal E/e')

This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).

,
InterventionRatio (Mean)
Diastolic Function (Baseline)Diastolic Function (12-month Follow-Up)
Placebo Control1513
Spironolactone1413

Reviews

4 reviews available for losartan and Cirrhosis

ArticleYear
Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2023, Volume: 39, Issue:3

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cicatrix; Corne

2023
Potential Usefulness of Losartan as an Antifibrotic Agent and Adjunct to Platelet-Rich Plasma Therapy to Improve Muscle Healing and Cartilage Repair and Prevent Adhesion Formation.
    Orthopedics, 2018, Sep-01, Volume: 41, Issue:5

    Topics: Animals; Antifibrinolytic Agents; Cartilage; Disease Models, Animal; Fibrosis; Humans; Losartan; Mus

2018
TGFβ signaling: its role in fibrosis formation and myopathies.
    Current opinion in rheumatology, 2012, Volume: 24, Issue:6

    Topics: Animals; Caveolin 3; Disease Models, Animal; Fibrosis; Humans; Losartan; MicroRNAs; Muscle, Skeletal

2012
Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
    Clinical therapeutics, 2006, Volume: 28, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Endothelium, Vascular; Fibrosis; H

2006

Trials

17 trials available for losartan and Cirrhosis

ArticleYear
Short-term Effects of Losartan on Cardiovascular Risk and Allograft Injury Biomarkers in Kidney Transplant Recipients.
    Transplantation proceedings, 2022, Volume: 54, Issue:4

    Topics: Albuminuria; Allografts; Biomarkers; Cardiovascular Diseases; Fibrosis; Heart Disease Risk Factors;

2022
Losartan to reduce inflammation and fibrosis endpoints in HIV disease.
    AIDS (London, England), 2021, 03-15, Volume: 35, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Fibrosis; HIV Infections

2021
Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial.
    HIV medicine, 2021, Volume: 22, Issue:8

    Topics: Anti-HIV Agents; Fibrosis; HIV Infections; Humans; Inflammation; Losartan; Lymphoid Tissue; Raltegra

2021
A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.
    PloS one, 2017, Volume: 12, Issue:4

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Drug Administration Sched

2017
Downregulation of Profibrotic Gene Expression by Angiotensin Receptor Blockers.
    Iranian journal of kidney diseases, 2018, Volume: 12, Issue:6

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Down-Regulation; Female; Fi

2018
The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure.
    Kidney international, 2014, Volume: 85, Issue:2

    Topics: Adult; Albuminuria; Aldosterone; Allografts; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Bi

2014
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.
    JACC. Heart failure, 2013, Volume: 1, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Drug Adm

2013
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.
    JACC. Heart failure, 2013, Volume: 1, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Drug Adm

2013
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.
    JACC. Heart failure, 2013, Volume: 1, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Drug Adm

2013
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.
    JACC. Heart failure, 2013, Volume: 1, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Drug Adm

2013
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.
    JACC. Heart failure, 2013, Volume: 1, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Drug Adm

2013
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.
    JACC. Heart failure, 2013, Volume: 1, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Drug Adm

2013
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.
    JACC. Heart failure, 2013, Volume: 1, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Drug Adm

2013
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.
    JACC. Heart failure, 2013, Volume: 1, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Drug Adm

2013
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.
    JACC. Heart failure, 2013, Volume: 1, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Drug Adm

2013
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female;

2015
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female;

2015
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female;

2015
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female;

2015
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female;

2015
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female;

2015
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female;

2015
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female;

2015
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female;

2015
Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
    Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:1

    Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathie

2012
Angiotensin II blockade in kidney transplant recipients.
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:2

    Topics: Adult; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Fe

2013
Angiotensin II blockade in kidney transplant recipients.
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:2

    Topics: Adult; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Fe

2013
Angiotensin II blockade in kidney transplant recipients.
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:2

    Topics: Adult; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Fe

2013
Angiotensin II blockade in kidney transplant recipients.
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:2

    Topics: Adult; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Fe

2013
[Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:10

    Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Chan

2002
[Serum TIMP-1 concentration in patients with chronic glomerulonephritis and the effect of losartan].
    Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2003, Volume: 23, Issue:9

    Topics: Adolescent; Adult; Chronic Disease; Female; Fibrosis; Glomerulonephritis; Humans; Kidney; Losartan;

2003
Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers

2004
Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:10

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Collagen; Double-Blind Method; Echocardiography

2005
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy.
    Blood pressure, 2006, Volume: 15, Issue:4

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Biomarkers; Bl

2006
Renal allograft protection with angiotensin II type 1 receptor antagonists.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2007, Volume: 7, Issue:1

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Carbazoles; Carvedilol; Cross-Over Studi

2007
Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
    Kidney international, 1999, Volume: 56, Issue:2

    Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Blood Pressure; Chronic Disease; Endothelins;

1999

Other Studies

162 other studies available for losartan and Cirrhosis

ArticleYear
Secreted protein acidic and rich in cysteine (SPARC) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1) increments by the renin-angiotensin system induce renal fibrosis in deoxycorticosterone acetate-salt hypertensive rats.
    European journal of pharmacology, 2022, Jan-05, Volume: 914

    Topics: ADAMTS1 Protein; Angiotensin II Type 1 Receptor Blockers; Animals; Desoxycorticosterone Acetate; Ext

2022
Angiotensin Type 2 and Mas Receptor Activation Prevents Myocardial Fibrosis and Hypertrophy through the Reduction of Inflammatory Cell Infiltration and Local Sympathetic Activity in Angiotensin II-Dependent Hypertension.
    International journal of molecular sciences, 2021, Dec-20, Volume: 22, Issue:24

    Topics: Angiotensin I; Angiotensin II; Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Hypertension

2021
Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits.
    Experimental eye research, 2022, Volume: 216

    Topics: Actins; Administration, Ophthalmic; Angiotensin II Type 1 Receptor Blockers; Animals; Cicatrix; Coll

2022
Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions.
    Iranian journal of kidney diseases, 2022, Volume: 1, Issue:1

    Topics: Aged; Animals; Antioxidants; Female; Fibrosis; Humans; Inflammation; Isoflavones; Kidney; Losartan;

2022
Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury.
    Translational vision science & technology, 2022, 07-08, Volume: 11, Issue:7

    Topics: Adrenal Cortex Hormones; Alkalies; Animals; Burns, Chemical; Cicatrix; Collagen Type IV; Corneal Dis

2022
Pan-Src kinase inhibitor treatment attenuates diabetic kidney injury via inhibition of Fyn kinase-mediated endoplasmic reticulum stress.
    Experimental & molecular medicine, 2022, Volume: 54, Issue:8

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Fibr

2022
Angiotensin-receptor blocker losartan alleviates atrial fibrillation in rats by downregulating frizzled 8 and inhibiting the activation of WNT-5A pathway.
    Clinical and experimental pharmacology & physiology, 2023, Volume: 50, Issue:1

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; A

2023
Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 149

    Topics: Animals; Fibrosis; Kidney; Kidney Diseases; Losartan; Male; Metabolic Networks and Pathways; Mice; M

2022
Integrin subunit β-like 1 mediates angiotensin II-induced myocardial fibrosis by regulating the forkhead box Q1/Snail axis.
    Archives of biochemistry and biophysics, 2022, 11-15, Volume: 730

    Topics: Angiotensin II; Animals; Cardiomyopathies; Extracellular Matrix Proteins; Fibroblasts; Fibrosis; Int

2022
Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience.
    Journal of refractive surgery (Thorofare, N.J. : 1995), 2022, Volume: 38, Issue:11

    Topics: Adult; Corneal Diseases; Corneal Opacity; Corneal Stroma; Female; Fibrosis; Humans; Keratomileusis,

2022
Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits.
    Journal of refractive surgery (Thorofare, N.J. : 1995), 2022, Volume: 38, Issue:12

    Topics: Animals; Collagen Type IV; Fibrosis; Losartan; Rabbits; Transforming Growth Factor beta; United Stat

2022
Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits.
    Journal of refractive surgery (Thorofare, N.J. : 1995), 2022, Volume: 38, Issue:12

    Topics: Animals; Collagen Type IV; Fibrosis; Losartan; Rabbits; Transforming Growth Factor beta; United Stat

2022
Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits.
    Journal of refractive surgery (Thorofare, N.J. : 1995), 2022, Volume: 38, Issue:12

    Topics: Animals; Collagen Type IV; Fibrosis; Losartan; Rabbits; Transforming Growth Factor beta; United Stat

2022
Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits.
    Journal of refractive surgery (Thorofare, N.J. : 1995), 2022, Volume: 38, Issue:12

    Topics: Animals; Collagen Type IV; Fibrosis; Losartan; Rabbits; Transforming Growth Factor beta; United Stat

2022
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158

    Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta

2023
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158

    Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta

2023
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158

    Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta

2023
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 158

    Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta

2023
Effects of Adjunct Antifibrotic Treatment within a Regenerative Rehabilitation Paradigm for Volumetric Muscle Loss.
    International journal of molecular sciences, 2023, Feb-10, Volume: 24, Issue:4

    Topics: Animals; Fibrosis; Losartan; Medicine; Motor Activity; Muscle, Skeletal; Muscular Diseases

2023
Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury.
    Pharmacology research & perspectives, 2023, Volume: 11, Issue:2

    Topics: Animals; Antioxidants; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies

2023
Bupi Yishen formula may prevent kidney fibrosis by modulating fatty acid metabolism in renal tubules.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 114

    Topics: Animals; Fatty Acids; Fibrosis; Humans; Kidney; Losartan; Rats; Renal Insufficiency, Chronic

2023
Effects of a Losartan-Antioxidant Hybrid (GGN1231) on Vascular and Cardiac Health in an Experimental Model of Chronic Renal Failure.
    Nutrients, 2023, Apr-10, Volume: 15, Issue:8

    Topics: Animals; Antioxidants; Fibrosis; Kidney; Kidney Failure, Chronic; Losartan; Male; Models, Theoretica

2023
Losartan in Combination With Bone Marrow Stimulation Showed Synergistic Effects on Load to Failure and Tendon Matrix Organization in a Rabbit Model.
    Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2023, Volume: 39, Issue:12

    Topics: Animals; Bone Marrow; Collagen Type I; Collagen Type III; Fibrosis; Losartan; Rabbits; Tendons; Tran

2023
Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway.
    Cardiovascular research, 2023, 08-07, Volume: 119, Issue:9

    Topics: Angiotensin II; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly;

2023
Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells.
    Archives of biochemistry and biophysics, 2023, 10-15, Volume: 748

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Epithelial Cell

2023
Losartan accelerates the repair process of renal fibrosis in UUO mouse after the surgical recanalization by upregulating the expression of Tregs.
    International urology and nephrology, 2019, Volume: 51, Issue:11

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Fibrosis; Kidney; Losartan; Male; Mice; Mice, Inb

2019
Comparison of the effects of pentoxifylline, simvastatin, tamoxifen, and losartan on cavernous bodies after penile fracture in rats: a stereological study.
    International journal of impotence research, 2020, Volume: 32, Issue:3

    Topics: Animals; Fibrosis; Losartan; Male; Penile Diseases; Pentoxifylline; Rats; Simvastatin; Tamoxifen

2020
Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model.
    Drug design, development and therapy, 2019, Volume: 13

    Topics: Animals; Atorvastatin; Disease Models, Animal; Fibrosis; Joint Capsule; Knee Injuries; Knee Joint; L

2019
Angiotensin receptor blockade mimics the effect of exercise on recovery after orthopaedic trauma by decreasing pain and improving muscle regeneration.
    The Journal of physiology, 2020, Volume: 598, Issue:2

    Topics: Angiotensin Receptor Antagonists; Animals; Fibrosis; Fractures, Bone; Hyperalgesia; Losartan; Mice;

2020
Increased angiotensin II from adipose tissue modulates myocardial collagen I and III in obese rats.
    Life sciences, 2020, Jul-01, Volume: 252

    Topics: Adipose Tissue; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Collagen Type I; C

2020
N-Acetyl-Seryl-Asparyl-Lysyl-Proline regulates lung renin angiotensin system to inhibit epithelial-mesenchymal transition in silicotic mice.
    Toxicology and applied pharmacology, 2020, 12-01, Volume: 408

    Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym

2020
Effect of Oral Losartan on Orthobiologics: Implications for Platelet-Rich Plasma and Bone Marrow Concentrate-A Rabbit Study.
    International journal of molecular sciences, 2020, Oct-06, Volume: 21, Issue:19

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Bon

2020
Dojuksan ameliorates tubulointerstitial fibrosis through irisin-mediated muscle-kidney crosstalk.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021, Volume: 80

    Topics: Animals; Cell Line; Collagen Type I; Drugs, Chinese Herbal; Fibronectins; Fibrosis; Kidney Diseases;

2021
Losartan prevents bladder fibrosis and protects renal function in rat with neurogenic paralysis bladder.
    Neurourology and urodynamics, 2021, Volume: 40, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibrosis; Losartan; Male;

2021
Impaired right and left ventricular function and relaxation induced by pulmonary regurgitation are not reversed by tardive antifibrosis treatment.
    American journal of physiology. Heart and circulatory physiology, 2021, 07-01, Volume: 321, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography; Fibrosis

2021
An organ-on-a-chip model for pre-clinical drug evaluation in progressive non-genetic cardiomyopathy.
    Journal of molecular and cellular cardiology, 2021, Volume: 160

    Topics: Angiotensin II; Animals; Cardiomyopathies; Cardiotonic Agents; Cell Line; Cell Survival; Coculture T

2021
Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney.
    Clinical science (London, England : 1979), 2021, 08-13, Volume: 135, Issue:15

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial

2021
EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 142

    Topics: Administration, Oral; Angiotensin II; Animals; Anti-Inflammatory Agents; Cannabidiol; Fibroblasts; F

2021
A girl with a mutation of the ciliary gene CC2D2A presenting with FSGS and nephronophthisis.
    CEN case reports, 2022, Volume: 11, Issue:1

    Topics: Child; Child, Preschool; Cytoskeletal Proteins; Female; Fibrosis; Glomerulosclerosis, Focal Segmenta

2022
Losartan Preserves Erectile Function by Suppression of Apoptosis and Fibrosis of Corpus Cavernosum and Corporal Veno-Occlusive Dysfunction in Diabetic Rats.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 42, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Collagen; Cyclic GMP; Diabetes Mellitu

2017
Effect of Losartan on Mitral Valve Changes After Myocardial Infarction.
    Journal of the American College of Cardiology, 2017, Sep-05, Volume: 70, Issue:10

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography, Three-Di

2017
Inhibition of angiotensin II and calpain attenuates pleural fibrosis.
    Pulmonary pharmacology & therapeutics, 2018, Volume: 48

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bleomycin; Calpain; Carbon; Cell L

2018
KLF 15 Works as an Early Anti-Fibrotic Transcriptional Regulator in Ang II-Induced Renal Fibrosis via Down-Regulation of CTGF Expression.
    Kidney & blood pressure research, 2017, Volume: 42, Issue:6

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Connective Tissue Growth Factor; D

2017
Endothelial transcriptomics reveals activation of fibrosis-related pathways in hypertension.
    Physiological genomics, 2018, 02-01, Volume: 50, Issue:2

    Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Fibrosis; Hea

2018
Transforming growth factor-β1 induces cerebrovascular dysfunction and astrogliosis through angiotensin II type 1 receptor-mediated signaling pathways.
    Canadian journal of physiology and pharmacology, 2018, Volume: 96, Issue:5

    Topics: Animals; Brain; Enalapril; Female; Fibrosis; Gliosis; Losartan; Male; Mice; Mice, Transgenic; Recept

2018
Angiotensin receptor blockade in juvenile male rat offspring: Implications for long-term cardio-renal health.
    Pharmacological research, 2018, Volume: 134

    Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Birth Weight; Blood

2018
Nigella sativa extract is a potent therapeutic agent for renal inflammation, apoptosis, and oxidative stress in a rat model of unilateral ureteral obstruction.
    Phytotherapy research : PTR, 2018, Volume: 32, Issue:11

    Topics: Angiotensin II; Animals; Apoptosis; Captopril; Chemokine CCL2; Creatinine; Fibrosis; Inflammation; K

2018
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
    The Journal of physiology, 2019, Volume: 597, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Lin

2019
Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction.
    Journal of cardiovascular pharmacology, 2019, Volume: 73, Issue:2

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin III; Animals; Brain; Dise

2019
The effects of losartan on cytomegalovirus infection in human trabecular meshwork cells.
    PloS one, 2019, Volume: 14, Issue:6

    Topics: Actins; Connective Tissue Growth Factor; Cytomegalovirus; Cytomegalovirus Infections; Enzyme-Linked

2019
Impact of early life AT
    European journal of pharmacology, 2019, Oct-05, Volume: 860

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Biomarkers; Cardiomyopathies; Di

2019
Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
    Journal of the American Heart Association, 2013, Apr-22, Volume: 2, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Epithe

2013
An Angiotensin receptor blocker prevents arrhythmogenic left atrial remodeling in a rat post myocardial infarction induced heart failure model.
    Journal of Korean medical science, 2013, Volume: 28, Issue:5

    Topics: Angiotensin Receptor Antagonists; Animals; Atrial Fibrillation; Atrial Remodeling; Disease Models, A

2013
Adverse biventricular remodeling in isolated right ventricular hypertension is mediated by increased transforming growth factor-β1 signaling and is abrogated by angiotensin receptor blockade.
    American journal of respiratory cell and molecular biology, 2013, Volume: 49, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Connective Tissue Growth Factor; Endoth

2013
Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis.
    Nephrology (Carlton, Vic.), 2013, Volume: 18, Issue:10

    Topics: Angiotensin II; Animals; Antioxidants; Cell Line; Class Ia Phosphatidylinositol 3-Kinase; Collagen T

2013
T₁ mapping detects pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-overload hypertrophy.
    Circulation. Cardiovascular imaging, 2014, Volume: 7, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Contrast Media; Disease Models, Animal; Dose-Respo

2014
Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2015, Volume: 16, Issue:3

    Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cell Movement; Cell Transdifferentiation; Chole

2015
Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy.
    Molecular medicine reports, 2014, Volume: 10, Issue:2

    Topics: Actins; Animals; Apoptosis; bcl-2-Associated X Protein; Collagen Type I; Dimethyl Sulfoxide; Disease

2014
Increased expression of (pro)renin receptor does not cause hypertension or cardiac and renal fibrosis in mice.
    Laboratory investigation; a journal of technical methods and pathology, 2014, Volume: 94, Issue:8

    Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Female; Fibrosis; Heart Ventricles; H

2014
Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats.
    American journal of physiology. Renal physiology, 2014, Nov-15, Volume: 307, Issue:10

    Topics: Albuminuria; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug

2014
Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury.
    Journal of applied physiology (Bethesda, Md. : 1985), 2014, Nov-15, Volume: 117, Issue:10

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Dose-Response Relationship

2014
Profibrosing effect of angiotensin converting enzyme inhibitors in human lung fibroblasts.
    Lung, 2015, Volume: 193, Issue:2

    Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril

2015
Activation of the renin-angiotensin system stimulates biliary hyperplasia during cholestasis induced by extrahepatic bile duct ligation.
    American journal of physiology. Gastrointestinal and liver physiology, 2015, Apr-15, Volume: 308, Issue:8

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bile Ducts, Extrahepatic; Cell Lin

2015
The role of KCa3.1 channels in cardiac fibrosis induced by pressure overload in rats.
    Pflugers Archiv : European journal of physiology, 2015, Volume: 467, Issue:11

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Aorta, Abdominal; Blood Pressure;

2015
TRIF promotes angiotensin II-induced cross-talk between fibroblasts and macrophages in atrial fibrosis.
    Biochemical and biophysical research communications, 2015, Aug-14, Volume: 464, Issue:1

    Topics: Adaptor Proteins, Vesicular Transport; Angiotensin II; Animals; Atrial Fibrillation; Cell Communicat

2015
Quiz page: an unusual cause of nephrotic syndrome.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 66, Issue:1

    Topics: Antihypertensive Agents; Collagen Diseases; Collagen Type III; Edema; Fibrosis; Humans; Hypertension

2015
Th-17 cell activation in response to high salt following acute kidney injury is associated with progressive fibrosis and attenuated by AT-1R antagonism.
    Kidney international, 2015, Volume: 88, Issue:4

    Topics: Acute Kidney Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultur

2015
Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A).
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibrosis; Laminin; Losarta

2015
Ets-1 upregulation mediates angiotensin II-related cardiac fibrosis.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:9

    Topics: Angiotensin II; Animals; Cell Proliferation; Collagen; Connective Tissue Growth Factor; Dose-Respons

2015
May the fibrosis be with you: Is discoidin domain receptor 2 the receptor we have been looking for?
    Journal of molecular and cellular cardiology, 2016, Volume: 91

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Collagen; Discoidin Domain Receptors; Fibroblasts;

2016
Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, 01-01, Volume: 32, Issue:1

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibroblast Gr

2017
Metabolomics study of renal fibrosis and intervention effects of total aglycone extracts of Scutellaria baicalensis in unilateral ureteral obstruction rats.
    Journal of ethnopharmacology, 2016, Nov-04, Volume: 192

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Discr

2016
Renal denervation significantly attenuates cardiorenal fibrosis in rats with sustained pressure overload.
    Journal of the American Society of Hypertension : JASH, 2016, Volume: 10, Issue:7

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cardiomyo

2016
Hypomethylation of Agtrap is associated with long-term inhibition of left ventricular hypertrophy in prehypertensive losartan-treated spontaneously hypertensive rats.
    Molecular medicine reports, 2017, Volume: 15, Issue:2

    Topics: Animals; Antihypertensive Agents; Blood Pressure; DNA Methylation; Fibrosis; Hypertension; Hypertrop

2017
Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites.
    Scientific reports, 2017, 02-03, Volume: 7

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line; Connective Tissue Growth Factor; Fibros

2017
Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation.
    Acta physiologica (Oxford, England), 2017, Volume: 220, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cardio-Renal Syndrome; Coronary Vess

2017
Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle.
    The American journal of sports medicine, 2008, Volume: 36, Issue:8

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Fibrosis; Losart

2008
N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster.
    Antioxidants & redox signaling, 2008, Volume: 10, Issue:12

    Topics: Acetylcysteine; Amidines; Angiotensin II Type 1 Receptor Blockers; Animals; Benzylamines; Cardiomyop

2008
[Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:12

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Losartan; M

2008
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
    JACC. Cardiovascular imaging, 2009, Volume: 2, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopri

2009
Losartan preserves erectile function after bilateral cavernous nerve injury via antifibrotic mechanisms in male rats.
    The Journal of urology, 2009, Volume: 181, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Erectile Dysfunction; Fibrosis; Losartan; Male; Pe

2009
Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat.
    Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals,

2009
Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.
    American journal of physiology. Renal physiology, 2009, Volume: 297, Issue:3

    Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Cyto

2009
Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system.
    Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:5

    Topics: Actins; Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I

2009
Heme oxygenase-1 inducer hemin attenuates the progression of remnant kidney model.
    Nephron. Experimental nephrology, 2009, Volume: 113, Issue:1

    Topics: Animals; Bone Morphogenetic Protein 7; Caspase 3; Disease Progression; Enzyme Induction; Fibrosis; G

2009
Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats.
    Biological & pharmaceutical bulletin, 2009, Volume: 32, Issue:8

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Urea Nitrogen; Blotting, Western; Cardiomyop

2009
Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.
    American journal of physiology. Renal physiology, 2010, Volume: 298, Issue:3

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An

2010
Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system.
    Journal of the American Society of Nephrology : JASN, 2010, Volume: 21, Issue:6

    Topics: Angiotensin I; Animals; Cells, Cultured; Chemokine CCL2; Collagen Type I; Connective Tissue Growth F

2010
Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse.
    American journal of physiology. Gastrointestinal and liver physiology, 2010, Volume: 299, Issue:1

    Topics: Actins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrophy; Ceruletide; Colla

2010
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
    American journal of physiology. Heart and circulatory physiology, 2010, Volume: 299, Issue:2

    Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr

2010
Losartan reduces mortality in a genetic model of heart failure.
    Naunyn-Schmiedeberg's archives of pharmacology, 2010, Volume: 382, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Angiotensin II Type 1 Receptor Blockers; Animals; Calsequestri

2010
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
    The Journal of nutrition, 2010, Volume: 140, Issue:10

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen

2010
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β.
    The Journal of clinical investigation, 2010, Volume: 120, Issue:10

    Topics: Animals; Bromodeoxyuridine; Cardiomyopathy, Hypertrophic; Cell Proliferation; Disease Models, Animal

2010
Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7.
    Circulation research, 2011, Jan-21, Volume: 108, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Cells, Cultur

2011
Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.
    Journal of cardiovascular pharmacology and therapeutics, 2011, Volume: 16, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomyopathies; Cell Adhesion Mo

2011
Angiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-β1 pathways in cardiac fibroblasts.
    Cardiovascular research, 2011, Jul-01, Volume: 91, Issue:1

    Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Adhesio

2011
Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signalling.
    Cardiovascular research, 2011, Jul-15, Volume: 91, Issue:2

    Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, New

2011
Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice.
    PloS one, 2011, Volume: 6, Issue:6

    Topics: Animals; Fibrosis; Heart; Heart Conduction System; Heart Function Tests; Losartan; Male; Mice; Mice,

2011
[Effect of losartan on renal expression of monocyte chemoattractant protein-1 and transforming growth factor-β(1) in rats after unilateral ureteral obstruction].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:8

    Topics: Animals; Chemokine CCL2; Fibrosis; Kidney; Losartan; Male; Rats; Rats, Sprague-Dawley; Transforming

2011
Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model.
    American journal of physiology. Renal physiology, 2012, Jan-01, Volume: 302, Issue:1

    Topics: Angiotensin II; Animals; Cell Degranulation; Fibrosis; Humans; In Vitro Techniques; Kidney; Kidney D

2012
Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 2012, Volume: 59, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Collagen; Disease Models, A

2012
Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Colitis; Disease Models, Animal; Disease Progressi

2012
[Investigate the effects of compound radix notoginseng on renal interstitial fibrosis and kidney-targeting treatment].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2012, Volume: 43, Issue:1

    Topics: Actins; Animals; Collagen Type I; Drugs, Chinese Herbal; Fibronectins; Fibrosis; Kidney; Losartan; M

2012
Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition.
    PloS one, 2012, Volume: 7, Issue:3

    Topics: Angiotensinogen; Animals; Cresols; Epithelial-Mesenchymal Transition; Fibrosis; Gene Expression Regu

2012
Losartan improves adipose tissue-derived stem cell niche by inhibiting transforming growth factor-β and fibrosis in skeletal muscle injury.
    Cell transplantation, 2012, Volume: 21, Issue:11

    Topics: Adipose Tissue; Animals; Coculture Techniques; Fibrosis; Immunoblotting; Losartan; Male; Mice; Mice,

2012
Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts.
    Experimental cell research, 2012, Oct-01, Volume: 318, Issue:16

    Topics: Angiotensin II; Animals; Connective Tissue Growth Factor; Fibroblasts; Fibrosis; Gene Expression; He

2012
The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload.
    The Journal of steroid biochemistry and molecular biology, 2012, Volume: 132, Issue:3-5

    Topics: Animals; Aorta; Atrial Natriuretic Factor; Blood Pressure; Collagen Type III; Disease Models, Animal

2012
(Pro)renin receptor triggers distinct angiotensin II-independent extracellular matrix remodeling and deterioration of cardiac function.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Adenoviridae; Angiotensin II; Animals; Apoptosis; Cell Proliferation; Enzyme Activation; Extracellul

2012
Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers.
    Circulation, 2012, Sep-11, Volume: 126, Issue:11 Suppl 1

    Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Cells, Cultured; Co

2012
Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: a pharmacologic dilemma on hepatocyte proliferation.
    The Journal of surgical research, 2013, Volume: 179, Issue:1

    Topics: Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents;

2013
Losartan alleviates renal fibrosis by down-regulating HIF-1α and up-regulating MMP-9/TIMP-1 in rats with 5/6 nephrectomy.
    Renal failure, 2012, Volume: 34, Issue:10

    Topics: Animals; Down-Regulation; Fibrosis; Kidney; Losartan; Male; Matrix Metalloproteinase 9; Nephrectomy;

2012
Losartan prevents heart fibrosis induced by long-term intensive exercise in an animal model.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, We

2013
Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice.
    Journal of the American Society of Nephrology : JASN, 2002, Volume: 13, Issue:10

    Topics: Actins; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cells, Cultured; Drug Synergism;

2002
Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria.
    The Journal of urology, 2002, Volume: 168, Issue:4 Pt 1

    Topics: Angiotensin Receptor Antagonists; Animals; Atrophy; Fibrosis; Hyperoxaluria; Kidney Tubules; Losarta

2002
Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation.
    Circulation, 2002, Oct-01, Volume: 106, Issue:14

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Blotting, Western; Diseas

2002
Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan.
    Chinese medical journal, 2002, Volume: 115, Issue:9

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Fibrosis; Fosinopril; H

2002
Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis.
    Circulation research, 2002, Dec-13, Volume: 91, Issue:12

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Cardiomyopathies; Cells

2002
[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats].
    Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, 2001, Apr-28, Volume: 26, Issue:2

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Fibrosis; Fosinopril; Hypertension; Losartan; Male

2001
Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.
    Transplantation, 2003, Feb-15, Volume: 75, Issue:3

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Arterioles; Blood Pressure; Body Weight; Chronic D

2003
Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis.
    Circulation, 2003, Sep-23, Volume: 108, Issue:12

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Cells, Cultured; Connective Tissue

2003
Angiotensin II dependent testicular fibrosis and effects on spermatogenesis after vasectomy in the rat.
    The Journal of urology, 2003, Volume: 170, Issue:5

    Topics: Acetylcysteine; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conv

2003
[Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction].
    Medicina, 2004, Volume: 64, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Fibrosis; Losartan; Myoca

2004
Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction.
    Kidney international, 2004, Volume: 65, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Cyclooxygenase 2; Female; Fibrosis;

2004
Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function.
    Molecular and cellular biochemistry, 2004, Volume: 260, Issue:1-2

    Topics: Animals; Blood Urea Nitrogen; Fibronectins; Fibrosis; Glomerular Filtration Rate; Ischemia; Kidney C

2004
Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system.
    American journal of hypertension, 2004, Volume: 17, Issue:7

    Topics: Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Biomarkers; Blood Pressure; Cyclic N-Ox

2004
Contribution of angiotensin II to alcohol-induced pancreatic fibrosis in rats.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 311, Issue:3

    Topics: Actins; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Captopril; C

2004
Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E.
    American journal of physiology. Heart and circulatory physiology, 2005, Volume: 288, Issue:1

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cells, Cultured; Col

2005
Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2004, Volume: 27, Issue:8

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apoptosis; A

2004
Angiotensin II mediates acinar cell apoptosis during the development of rat pancreatic fibrosis by AT1R.
    Pancreas, 2004, Volume: 29, Issue:4

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Disease Models, Animal;

2004
Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist.
    Journal of cardiovascular pharmacology, 2005, Volume: 45, Issue:1

    Topics: Adrenergic beta-Agonists; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Anim

2005
Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.
    Circulation, 2005, Jun-14, Volume: 111, Issue:23

    Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Angiotensin II; Angiotensinogen; Animals; Animals, Genet

2005
Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy.
    Transplantation, 2005, Jun-15, Volume: 79, Issue:11

    Topics: Animals; C-Reactive Protein; Cyclosporine; Disease Models, Animal; Fibrosis; Inflammation; Kidney; K

2005
Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP 70) expression in obstructive nephropathy.
    Cellular and molecular biology (Noisy-le-Grand, France), 2005, Nov-08, Volume: 51, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Female; Fibrosis; Gene Expression

2005
Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells.
    World journal of gastroenterology, 2005, Nov-07, Volume: 11, Issue:41

    Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cell Division; Cell Movement; Cells, Cultured; F

2005
Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy.
    American journal of nephrology, 2006, Volume: 26, Issue:1

    Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzamides; Diabetic Nephropathies; D

2006
Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction.
    The Journal of urology, 2006, Volume: 176, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Los

2006
Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice.
    Nephron. Experimental nephrology, 2007, Volume: 105, Issue:2

    Topics: Albuminuria; Animals; Antihypertensive Agents; Benzamides; Diabetic Nephropathies; Disease Models, A

2007
Prevention of interstitial fibrosis of renal allograft by angiotensin II blockade.
    Transplantation proceedings, 2006, Volume: 38, Issue:10

    Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Cyclosporine; Female; Fibrosis; Huma

2006
Chronic blockade of angiotensin II AT1-receptors increased cell-to-cell communication, reduced fibrosis and improved impulse propagation in the failing heart.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2006, Volume: 7, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomyopathy, Dilated; Cell Communication; Crice

2006
[Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile duct-ligated rats].
    The Korean journal of hepatology, 2007, Volume: 13, Issue:1

    Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Bile Ducts; Captopril; Fibrosis; Hydroxypr

2007
Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis.
    International journal of cardiology, 2008, Mar-28, Volume: 125, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Autoanti

2008
Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats.
    Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:5

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Benzoates;

2008
Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome.
    European journal of pharmacology, 2008, Jun-10, Volume: 587, Issue:1-3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Calcium

2008
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:3

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biopsy; Creatinine; Femal

2008
Effect of angiotensin II blockade on the fibroproliferative response to phenylephrine in the rat heart.
    Hypertension (Dallas, Tex. : 1979), 1995, Volume: 25, Issue:4 Pt 2

    Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blotting, Nor

1995
Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone.
    Hypertension (Dallas, Tex. : 1979), 1995, Volume: 26, Issue:1

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biochemical Phen

1995
Angiotensin II receptor binding following myocardial infarction in the rat.
    Cardiovascular research, 1994, Volume: 28, Issue:11

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Autoradiography; Biphenyl Compounds; Coll

1994
Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure.
    The Journal of clinical investigation, 1996, Jul-15, Volume: 98, Issue:2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic;

1996
The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis.
    The American journal of physiology, 1996, Volume: 271, Issue:5 Pt 1

    Topics: Aldosterone; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Body Weight; Canr

1996
Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart.
    The Journal of laboratory and clinical medicine, 1997, Volume: 129, Issue:4

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun

1997
Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis.
    Kidney international, 1998, Volume: 53, Issue:4

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Apoptosis; Argin

1998
Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart.
    Journal of molecular and cellular cardiology, 1998, Volume: 30, Issue:8

    Topics: Angiotensin II; Animals; Collagen; Fibrosis; Losartan; Male; Myocardial Infarction; Myocardium; Pept

1998
Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade.
    Kidney international, 1998, Volume: 54, Issue:5

    Topics: Angiotensin II; Animals; Blood Pressure; Body Weight; Eating; Enalapril; Fibronectins; Fibrosis; Glo

1998
Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo.
    Circulation, 1998, Dec-15, Volume: 98, Issue:24

    Topics: Aldosterone; Angiotensin II; Animals; Arterioles; Blood Pressure; Cell Division; Collagen; Coronary

1998
Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats.
    Journal of molecular and cellular cardiology, 1999, Volume: 31, Issue:2

    Topics: Angiotensin Receptor Antagonists; Animals; Cell Size; Female; Fibrosis; Heart Ventricles; Hypertroph

1999
Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats.
    Journal of hypertension, 1999, Volume: 17, Issue:1

    Topics: Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Blotting, Northern; Cardiomyopathies;

1999
Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells.
    Kidney international, 1999, Volume: 56, Issue:2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Anti-Bacterial Agents; Antihypertensive Agents; Bl

1999
Permanent cardiovascular protection from hypertension by the AT(1) receptor antisense gene therapy in hypertensive rat offspring.
    Circulation research, 1999, Nov-12, Volume: 85, Issue:10

    Topics: Animals; Animals, Newborn; Antihypertensive Agents; Aorta; Blood Pressure; DNA, Antisense; Fibrosis;

1999
Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 2000, Volume: 35, Issue:6

    Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Collagen; Collagenases; Extracellular Mat

2000
[Preventional intervention of myocardial interstitial fibrosis in murine myocardium with acute myocarditis].
    Zhonghua yi xue za zhi, 1998, Volume: 78, Issue:9

    Topics: Animals; Coxsackievirus Infections; Enterovirus B, Human; Fibrosis; Losartan; Male; Mice; Mice, Inbr

1998
Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat.
    Hypertension (Dallas, Tex. : 1979), 2000, Volume: 36, Issue:5

    Topics: Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Diseases; Heart Ventricles; Hypertens

2000
Effect of chronic angiotensin II inhibition on the cardiovascular system of the normal rat.
    American journal of hypertension, 2000, Volume: 13, Issue:12

    Topics: Angiotensin II; Animals; Aorta; Blood Pressure; Body Weight; Cardiovascular System; Collagen; Cyclic

2000
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.
    Circulation, 2001, Feb-13, Volume: 103, Issue:6

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co

2001
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.
    Circulation, 2001, Feb-13, Volume: 103, Issue:6

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co

2001
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.
    Circulation, 2001, Feb-13, Volume: 103, Issue:6

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co

2001
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.
    Circulation, 2001, Feb-13, Volume: 103, Issue:6

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Co

2001
Influence of the renin-angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney.
    Kidney international, 2001, Volume: 60, Issue:3

    Topics: Angiotensin II; Animals; Apoptosis; Blood Pressure; Cyclosporine; Diet, Sodium-Restricted; Epidermal

2001
The expression of AT1 receptor on hepatic stellate cells in rat fibrosis induced by CCl4.
    Chinese medical journal, 2001, Volume: 114, Issue:6

    Topics: Alanine Transaminase; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartate A

2001
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
    Circulation, 2002, Feb-12, Volume: 105, Issue:6

    Topics: Aldosterone; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Natriuretic Factor; Bo

2002
One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites.
    Journal of gastroenterology, 2002, Volume: 37, Issue:3

    Topics: Aged; Antihypertensive Agents; Ascites; Creatinine; Female; Fibrosis; Humans; Kidney; Losartan; Male

2002
Does angiotensin II type 1 receptor blockade offer a clinical advantage to cirrhotics with ascites?
    Journal of gastroenterology, 2002, Volume: 37, Issue:3

    Topics: Antihypertensive Agents; Ascites; Fibrosis; Humans; Losartan; Renal Plasma Flow, Effective; Sodium

2002